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Hip osteoarthritis is an increasingly important cause of morbidity in the ageing population
causing pain, disability and loss of function through joint failure. It has an estimated lifetime
risk of 25%. While the contribution of skeletal morphology to disease is now established, the
lack of imaging biomarkers that can reliably predict osteoarthritis development is limiting.
Novel biomarkers for clinically relevant hip osteoarthritis are needed particularly methods
to identify patients who are destined for total hip replacement (THR) surgery and who
might benefit from novel interventions. The chosen techniques studied here involved 2D
and 3D measures of hip cortical bone structure from routine clinical computed tomography
(CT) scans of patients to predict clinically-relevant hip osteoarthritis. Outside the research
environment, clinical practice and trials still use simple 2D outcome measures from radio-
graphs. Clinical diagnosis and surgical decision making therefore rely on combinations of
poorly-defined disease signs and symptoms and controversially, 2D radiographic imaging.
Such methods overlook key 3D disease features. In many osteoarthritis guidelines, clinicians
are now advised to avoid imaging altogether.
This work asked three important research questions concerning hip osteoarthritis.
1. Does imaging have clinical utility in managing patients with hip pain, and in particular
are hip radiographs e↵ective in predicting THR?
2. Does 3D imaging using clinical CT have clinical utility in predicting THR, and is there
a 3D phenotype of bone thickening associated with eventual THR?
3. Is the 3D bone thickening associated with hip osteoarthritis an inevitable consequence
of ageing?
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In order to answer these, CT cortical thickness data was acquired from two population based
studies; one in only older men and women from the Age, Gene/Environment Susceptibility-
Reykjavik (AGES) Study in Iceland and the other from the Mindways study acquired from
11 healthcare centres around the USA, of women aged 20-97 years.
CT scans were coupled with new image analysis techniques called 3D cortical bone thickness
mapping, statistical parametric mapping and disease feature distribution mapping. Recently
it was hypothesised that focal bone thickening in regions of the hip cortex would be associated
with eventual hip joint replacement and radiological progression of osteoarthritis features.
Combining hip pain, radiographic osteoarthritis grade and CT gave excellent discrimination
of THR (0.90;0.85,0.95). Conversely, hip pain was a poor to marginal predictor (AUC=0.70;
95%CI 0.62,0.78). The AUC for radiographic Kellgren and Lawrence (K&L) osteoarthritis
grade alone was 0.87(0.81,0.92), irrespective of hip pain, with single mJSW being a rea-
sonable discriminator (0.80;0.73,0.87). Osteoarthritis was also associated with a CT-defined
crescent of femoral head surface bone thickening (Odds Ratio for THR; 5 per SD thicker;
5.0(3.2,7.7), 0.85(0.79,0.91)). In a typical clinical presentation with hip pain, all of the
imaging parameters measured ranged from good to excellent in terms of clinical utility.
Imaging unequivocally predicted THR for osteoarthritis, whether or not pain had become
apparent. Contrary to current guidelines, images of patients with hip pain have good to ex-
cellent clinical utility for selecting surgically-relevant presentations. If patients with definite
hip pain had definite radiological osteoarthritis, 85% went on to THR within 3 years.
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Thesis Overview
In this study my research aims are to establish phenotypes of hip structure that are predictive
of osteoarthritis as potential novel biomarkers.
I aim to discover the clinical utility of existing 2D radiographic and novel 3D CT measures
in managing patients with hip pain by testing the following hypotheses.
1. 2D imaging will have clinical utility in predicting hip replacement in those with hip
pain.
2. The 3D distribution of cortical bone thickness around the proximal femur will predict
hip replacement in those with hip pain.
3. The 3D printed model of the SPM osteoarthritis ROI result will help with the under-
standing of OA disease features.
4. The distribution of cortical bone in the femoral head will become “osteoarthritic” with
ageing which will manifest as regional “thickening”.
Key Questions
The clinical utility of any imaging biomarkers is paramount. How will it be useful among
patients presenting with osteoarthritis signs and symptoms in the clinic? Is imaging reli-
ably associated with pain? Does it reliably predict hip replacement? For this, predictive
diagnostic methodology including receiver operating characteristic analysis will be needed.
Turmezei et al published a method for manual classification of hip osteoarthritis, describing
radiological CT features related to clinical osteoarthritis [1, 2]. My premise is that the
systematic global evaluation of subchondral thickening of the femoral head may be the
single most important factor of those measured (such as cysts, osteophyte load and joint
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Chapter 1
Hip Joint, Bone And Osteoarthritis
1.1 Introduction
This chapter provides a detailed, yet concise overview of the hip joint, the synovial joint
structure and the cells that make up bones. It introduces anatomical and physiological
information necessary to understand what e↵ect a disease (its symptoms, signs and diagnosis)
such as osteoarthritis (OA) has on joint anatomy.
1.2 The Hip Joint In Health And Osteoarthritis
The hip joint is a multiaxial synovial ball and socket joint that consists of the head of the
femur and the acetabulum of the pelvis, see Figure 1.1. It represents the articulation of the
bones of the lower limb and the axial skeleton. It is not only designed for stability and weight
bearing but also provides a large articulation area for all essential movement in everyday
activities such as: standing, walking and basic leg rotation.
The hip joint is an integral part of daily activities such as sitting, walking and running.
The specific anatomy and bio-mechanics of the hip joint is the consequence of evolution
and constant bipedal gait. The anatomy of the acetabulum and femoral bone ensures hip
stability throughout a wide range of motion. Any abnormality in this precise and delicate
anatomy can lead to potential instability and/or impingement within the hip joint. This
in turn becomes a risk factor for the development of osteoarthritis. The main forces that
act on the hip joint and the muscles around the hip are gravitational forces. Depending on
the activity, the hip may be subjected to a peak force of up to eight times a person’s body
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weight.[3] This makes the hip joint especially prone to “wear and tear”. The hip joint is said
to be the third most susceptible (after hand and knee) joint to develop osteoarthritis.[4–7]
Figure 1.1: Right Hip Joint Anatomy
Used from OpenStax, under a Creative Commons Attribution License (4.0) c 
The rounded head of the femur, which sits within the concavity of the acetabulum is entirely
covered by hyaline cartilage with the exception of a small area known as the fovea capitis
femoris. The ligament of the head of the femur (ligamentum teres) spans between capitis
femoris and the acetabulum. The hip joint capsule is lined by the synovium, which produces
synovial fluid that nourishes the cartilage and lubricates the joint.
The acetabulum is the part of the pelvis formed where three bones (ischium, ilium and pubis)
merge. At the centre of the acetabulum is a non-articulating surface known as the acetabular
fossa. This part of the acetabulum is not covered by hyaline cartilage and connects to the
ligament of the femoral head. The cartilage of the acetabular surface is thickest at the
periphery whereas cartilage of the femoral head is thickest on the medial-central surface.
The acetabulum is further deepened by the acetabular labrum, a fibrocartilaginous collar
attached to the outer margin of the acetabulum. It expands the depth of the joint increasing
its stability and positioning.
The surrounding articular joint capsule is robust and can accommodate a wide range of
movement. Ligaments arise from the pelvic bones, at the margins of the acetabulum, and
attach to the femur at the base of the neck, see Figure 1.2. The ligaments are the iliofemoral
ligament, pubofemoral ligament, and ischiofemoral ligament, all of which are arranged in a
spiral fashion around the head and neck of the femur. The ligaments are tightened by
extension at the hip, therefore they pull the femoral head tightly into the acetabulum when
in the upright, standing position. These ligaments stabilise the hip joint and allow one
to maintain an upright standing position with minimal muscle contraction preventing the
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hyperextension of the hip as well as excessive abduction.
(a) Anterior View Of Right Hip Joint (b) Posterior View Of Right Hip Joint
Figure 1.2: Ligaments Of The Hip Joint
Used from OpenStax, under a Creative Commons Attribution License (4.0) c 
The hip joint capsule is strengthened and reinforced by three ligaments (bands of tough,
flexible fibrous connective tissue):
• Anteriorly and superiorly, see Figure
1.3 by the iliofemoral ligament which
connects the anterior, inferior iliac
spine and the acetabular rim to the
femoral intertrochanteric line (it is the
strongest of the femoral ligaments).
• Inferiorly and anteriorly the pub-
ofemoral ligament arises from the ob-
turator crest and the superior ramus of
the pubis and blends with the capsule
and the medial part of the iliofemoral
ligament.
• The ischiofemoral ligament connects
the ischial part of the acetabular rim
to the neck of the femur.




A lot of force is needed to move the femur, hip and legs so the muscles of the hip generally
tend to be large and powerful, see Figure 1.4. Anterior muscles of the femur extend the
lower leg but also assist with the flexing of the thigh. Posterior muscles of the femur flex
the lower leg but also assist with the extension the thigh. The gluteal and thigh muscles
adduct, abduct, and rotate the thigh and the lower leg. The gluteus maximus, the piriformis,
obturator internus, obturator externus, superior gemellus, inferior gemellus, and quadratus
femoris are responsible for rotatating the femur at the hip. The adductor longus, adductor
brevis, and adductor magnus are responsible for the rotatation of the thigh both medially
and laterally. The adductor longus flexes the thigh, whereas the adductor magnus extends
it and the pectineus also adducts and flexes the femur at the hip. The medial muscles are
responsible for adducting the femur at the hip.
(a) Anterior View Of Pelvic And Thigh
Muscles Of The Right Leg
(b) Posterior View Of Pelvic And Thigh
Muscles Of The Right Leg
Figure 1.4: Muscles Of The Pelvis And Thigh
Used From OpenStax, Under A Creative Commons Attribution License (4.0) c 
Combined, these muscles allow for hip rotation in multiple planes. Flexion and extension
(sitting down), internal and external rotation (twisting actions), and abduction and adduc-
tion (inward and outward motion of the hip in cross legged actions).
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1.3 Synovial Joint Structure
Basic structure of a synovial joint consists of two opposing units of subchondral bone with
overlying articular cartilage interposed by a layer of synovial fluid, see Figure 1.5.
Figure 1.5: Structural Representation (Not To Scale) Of A Typical Synovial Joint
Synovial Fluid
Synovial fluid is clear and its viscosity decreases causing it to thin under shear strain. This
“thixotropic” property means that it becomes more elastic as the rate of joint movement
increases. As forces are added to a joint, synovial fluid is squeezed out from between
opposing joint ends and the force is resisted by the tenacity of the fluid itself ensuring that
any friction produced by weight or movement will occur with the fluid rather than between
the cartilage surfaces of the bone joints. Synovial fluid is very similar to blood plasma
except for the fact that it does not contain fibrinogen or prothrombin and so is unable
to clot. The most important component of synovial fluid is a substance called sodium
hyaluronate (secreted by the synovicytes) however it also contains mucin, albumin, fat,
epithelium, and leukocytes.[8, 9] A typical hip joint contains very little synovial fluid (9.5-
4ml).[10] Synovial fluid is responsible for a number of di↵erent functions at the same time.
Synovial fluid creates a separation area to keep joint bones apart (protecting their cartilage
coverings from damage and wear), it absorbs shock, it lubricates the joint helping it move
and work without friction and it also responsible for nourishing the avascular cartilage.[11]
Norris et al. has shown that when a joint is injured, synovial fluid volume may increase
as much as 10-20 times. As the volume of synovial fluid volume increases, hyaluronate
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decreases and as this decrease occurs the viscosity of synovial fluid also decreases. It is
said that the excess accumulation of synovial fluid volume itself does not cause pain, but
it is the speed with which it forms.[12] Blau et al. claimed that as much as 100ml synovial
fluid can be extracted from a joint without causing much pain, while a 15ml increase may
cause excruciating pain if formed rapidly following a trauma.
Articular Cartilage
Articular cartilage is a thin covering (1-3mm) on the ends of bones that creates mov-
ing surfaces of synovial joints.[13, 14] Articular cartilage functions as a shock absorber
and reduces friction between bones inside a joint. The articular cartilage covering the
subchondral bone plate (of the femur and acetabulum bone) is a specific type known
as hyaline cartilage. Radiographic assessment of cartilage in non-osteoarthritis hips has
shown that cartilage thickness on the acetabular and femoral sides is not identical. As
mentioned in Section 1.2, acetabular cartilage is thicker peripherally than centrally, and
femoral cartilage is thinner peripherally than centrally.[15] Articular cartilage consists of
fibres, ground substance and cells. The fibres are primarily composed of numerous di↵er-
ent long-chained extra-cellular matrix molecules (type II collagen,[16] proteoglycans,[17]
glycosaminoglycans[18] and chondroitin sulfate[19]) that are essential for structural in-
tegrity. Collagen provides cartilage with necessary tensile strength that ensures smooth
gliding of opposing articular surfaces in a bone joint. Type II collagen makes up 55-75%
cartilages dry weight.[20] The ground substance consists of proteoglycans and glycosamino-
glycans (15-30%) as well as water (70-80%).[21–23] Various glycans present have unique
bonds with water molecules that ensure articular cartilage can easily resist and redistribute
compressive forces. These molecules are incorporated in an aqueous environment with a
relatively small volume (<1% of overall cartilage mass) of cartilage cells called chondro-
cytes (both collagen and proteoglycans are produced by chondrocytes). The structure of
cartilage tissue is relatively simple, and it does not contain nerves or blood vessels. If there
is constant compression on articular cartilage there will be a decrease in the di↵usion rate




The subchondral bone plate is one of the key structures that is evaluated using imaging in
this thesis. The plate is a layer of bone underneath the cartilage in the hip. Subchondral
bone is an extension of the already shock absorbing articular cartilage and is also able to
absorb some shock. Unlike the avascular layer of cartilage above, subchondral bone has
many blood vessels supplying it with all necessary nutrients and oxygen, the vessels also
remove any waste products produced. These blood vessels are not only essential for the
subchondral bone but provide over half of the hydration, oxygenation, and glucose for the
cartilage above.[26]
Subchondral Trabecular Bone
Subchondral trabecular bone, also known as cancellous or spongy bone, is an extremely
porous type of bone which is highly vascularised and in young adults contains red bone
marrow. The marrow spaces amid the trabecular rods and plates give it the “spongy”
appearance. This bone is softer and weaker than cortical bone, but this also makes it
more flexible and adaptable to any extra forces that may add pressure to it. The micro-
architecture of the subchondral bone adapts to its local environment and this includes any
mechanical loading from everyday forces.[27, 28] Both subchondral trabecular bone and
the subchondral bone plate contain numerous cells called osteocytes with small cavities
known as lacunae, forming a lattice-like matrix network. Blood vessels travel through the
harder compact bone to the trabecular bone.
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1.4 Structure Of Bone
A human skeleton contains a approximately 42 billion osteocytes interconnected inside a
matrix of mineralized collagen fibres. Inside this matrix, hydroxyapatite crystals form to give
bone its strength and density, while the collagen fibres provide bone with enough flexibility
to not be brittle. Although bone cell numbers are relatively small by tissue volume, they
are crucial to the function of bones. The four main types of cells that make-up bone are
osteoblasts, osteocytes, osteogenic cells, and osteoclasts, see Figure 1.6.
Figure 1.6: Typical Cells That Make Up Bone
Used From OpenStax, Under A Creative Commons Attribution License (4.0) c 
1.4.1 Bone Cells
Osteoblasts (Bone Builders)
Teams of osteoblasts form new bone (osteoid) by secreting collagen matrix particularly
during skeletal growth and remodelling. Osteoblasts do not divide but can terminally
di↵erentiate into osteocytes. They can also become inactive flat lining cells. The osteoblast
becomes trapped within osteoid and changes its morphology to become an osteocyte.
Osteocytes (Bone Maintainers)
Osteocytes are located in a space in the matrix (lacuna) surrounded by mineralized bone
tissue. Like osteoblasts, from which they developed, osteocytes cannot divide and lack
mitotic activity. They normally communicate with one another via long cytoplasmic





Osteogenic stem or “stromal” cells are undi↵erentiated cells and the only bone cells that
are able to do undergo mitosis. Osteogenic cells are normally found in the deep layers of
the bone and marrow. They are the cells which di↵erentiate and develop into osteoblasts
as and when necessary.
Osteoclasts (Bone Resorbers)
The nature of bone is extremely dynamic and as new tissue is constantly formed, the old,
injured or unnecessary bone is dissolved for repair to release more calcium for nutrition.
Osteoclasts are the cells responsible for the resorption of bone. They are normally found
on bone surfaces and are multinucleated cells that originate from monocyte fusion. Os-
teoclasts continually break down old bone while osteoblasts continually form new bone
and this balance is essential for the healthy reshaping of bone, if any of these processes
are disrupted or halt there may be a devastating e↵ect of bone health.
Figure 1.7: Spongy Bone Structure
Used From OpenStax, Under A Creative Commons Attribution License (4.0) c 
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1.4.2 Bone Modelling And Remodelling
Formal bone growth, comes to an end at puberty. About 90% of adult bone is formed by the
end of adolescence and the continuous process of remodelling begins to occur. A schematic
of bone remodelling in cortical and cancellous bone, see Figure 1.8. Bone remodelling is
responsible for maintaining bone health and ensuring that bones adapt to life and circum-
stantial changes. As the body ages, bone loses strength and elasticity (due to loss of mineral
and matrix volume), therefore it is more likely to fracture and break in older individuals.
All bones go through the process of remodelling in order to: mobilise calcium, replace old
tissue, adapt to di↵erent loads and weight-bearing stress and to repair damaged bone from
micro-fractures or micro-damage. As people age and remodelling occurs more and more fre-
quently, all of these repair processes weaken older bone and increase the risk of bone diseases
and fractures (especially if bone remodelling doesn’t occur quickly enough or is not allowed
the opportunity to complete its process before more damage).
(a) Cortical (Compact) Bone Modelling (b) Cancellous (Spongy) Bone Modelling




Cortical (compact) bone, see Figure 1.9, forms the hard outer shell of all bones. It is the
strongest and densest form of bone in the body. It is a compact bone which makes up nearly
80% of the skeletal mass. Cortical bone is vital to maintain the structure of the body. Its
high resistance to torsion and bending makes it ideal for weight bearing. As stress is applied
to particular regions of the body, the thickness of cortical bone adapts and varies over time.
Cortical bone is mainly made of osseous tissue. This osseous tissue consists of osteocytes,
surrounded by a solid inter-cellular matrix of minerals and protein fibres. Structurally,
cortical bone is made of osteons. Osteons are formed at the foetal stage of development
when blood vessels and nerve fibres pass through mesenchymal tissue containing osteogenic
cells. The ring of bone matrix is formed of these osteogenic cells, known as a lamella. As soon
as the lamella has formed, osteogenic cells become known as osteocytes. These osteocytes
remain in the osseous tissue in cavities known as lacunae. Canals known as canaliculi,
provide osteocytes with nutrients and oxygen from the surrounding blood vessels. During
the developmental process, this process repeats itself forming concentric layers of lamellae.
Figure 1.9: Cortical Bone Structure
Used From OpenStax, Under A Creative Commons Attribution License (4.0) c 
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1.4.4 Cortical Bone Mapping
Cortical bone mapping (CBM) is a technique that can be used to measure localised skeletal
changes from computed tomography (CT) images. CBM can provide detailed measure-
ments with far more accuracy than “simple full width half maximum estimations” from
low-resolution QCT data, with good di↵erentiation between thickness, density, and mass.
It can detect changes in numerous properties of the bone cortex, with no prior assumptions
about the likely location of changes.[29]
The CBM technique has already been used to reveal associations between fracture risk and
cortical properties in specific regions of the proximal femur which present feasible therapeutic
targets.[30] Where results demonstrated that CBM predicts fracture type better than bone
mineral density measurements alone. CBM has been successfully implemented to to reveal
associations between fracture risk and cortical properties in particular regions of the proximal
femur (which present feasible therapeutic targets). CBM has been used to assess the joint
space width,[31] which is indicative of cartilage thickness and therefore important in the
evaluation of osteoarthritis. CBM measures in men and women have been shown to predict
fracture type better than bone mineral density measurements alone. Although most work
has been conducted at the femur, CBM has also been shown to measure the vertebral cortex
accurately, allowing estimation of osteoporosis treatment responses.
The CBM technique is not limited to only CT data and has been successful in assessing
cartilage thickness directly, at the knee using magnetic resonance imaging (MRI).[32] If CT
data of the same area was to be used it would have only shown cartilage thickness inferred
indirectly from the joint space. CBM however has never been used in a study predicting
THR and hip pain and very minimally used to understand how osteoarthritis-prone parts of
the femoral head cortex change with age. This is where my study and this thesis comes it.
It will address these gaps in the knowledge. It will do so by applying the CBM technique
combined with statistical parametric mapping (SPM) on a gathered cohort of participants
complete with hip pain data.
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1.5 Osteoarthritis Of The Hip
While hip osteoarthritis is typically referred to as a degenerative disease, it actually results
in constant new tissue growth, the problem is that it is normally in the form of irregular
cartilage and osteophytes,[33] and thus even though there is cartilage growth it is detrimental
growth.
In epidemiological surveys the definition of hip osteoarthritis is often based on symptoms,
clinical signs, radiological signs or a combination of any of these.[34] In orthopaedics and
rheumatology, the definition of hip osteoarthritis is a combination of joint pain, sti↵ness and
radiographic changes such as loss of joint space width, osteophytes, cysts and sclerosis.[35]
Typical physical changes that occur in hip osteoarthritis are demonstrated by Figure 1.10.
(a) Normal Hip Joint (b) Osteoarthritic Hip Joint
Figure 1.10: Normal vs Osteoarthritic Hip
Used From OpenStax, Under A Creative Commons Attribution License (4.0) c 
When hip cartilage has deteriorated:
• New cartilage may be produced, but the new cartilage cells will grow in irregular, bumpy
patterns, rather than smooth. The result is that the femur and pelvic bones rub and grind
against one another.
• The bones may produce small, scalloped growths called osteophytes, to compensate for
the deteriorated cartilage. In turn, the osteophytes can create even more friction.
• Tendons and ligaments can also be stretched or otherwise compromised in an attempt to




Osteoarthritis is a progressively degenerative disease of a joint and a major cause of pain
and disability in older adults. Not only does it cause damage and loss of hyaline articular
cartilage but there is also remodelling of the sub-articular bone, ligaments laxity, osteophyte
formation, weakening of the periarticular muscles and synovial inflammation.[36, 37] As the
cartilage, which normally cushions the joint by reducing friction (and serves as a “pressure
absorber”) becomes damaged, it prevents smooth movement of the joint. Although cartilage
may undergo some repair (very minimal) after becoming damaged, the body does not easily
regenerate cartilage after it is injured[38, 39] and persistent re-injury is very common.[40]
Cartilage damage itself does not cause pain because cartilage does not contain nerve endings
that could signal pain to the brain, pain is usually sensed by the bone and other non-
cartilage tissues. Osteoarthritis can be a particularly debilitating form of arthritis because
it tends to heavily a↵ect load-bearing joints such as the hips and knees (both of which are
crucial to maintain normal movement). In 2013 the World Health Organization classified
osteoarthritis as the most common condition a↵ecting the musculoskeletal system and one
of the fastest increasing global health problems.[41] There has been a 20% increase in cases
of arthritis since 2002; of the >54 million US adults (23%) reporting arthritis diagnosed by
a doctor, almost 60% are below the usual retiring age.[42] Estimates from the US suggest
that hip replacements for osteoarthritis will increase 174% by 2030.[43] Globally, systematic
osteoarthritis a↵ects an estimated 18% of women and 9.6% of men over the age of 60, 80% of
those with osteoarthritis will have limitations in movement, and 25% cannot perform their
major daily activities of life.[44] In economically developed countries, osteoarthritis has been
reported in 40% of those 70 years of age and over.[45] Hip osteoarthritis has a radiographic
prevalence of 2.3% among women and 1.9% among men over the age of 45 years.[46]
At present, little is known about the pathogenesis of primary osteoarthritis and early de-
tection is very challenging. Surgical interventions for early stage osteoarthritis, such as
regenerative treatments,[47] are limited, due in part to the lack of accurate quantification of
disease severity and in particular early-stage disease features using current diagnostic imag-
ing methods. This often means that current osteoarthritis treatment is limited to analgesics,
weight loss and physical therapy exercises, where appropriate, often until joint damage and
pain are serious enough to warrant a total joint replacement. The number of joint replace-
ments has been increasing annually[48] and is likely to continue to increase exponentially,[43]
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this will likely be a huge burden for health-care systems around the world not to mention,
increased costs for the already stretched health-care economic budgets.
Hip osteoarthritis is central to this thesis, and yet it is hard to reach an acceptable consensus
on its definition. The definition of hip osteoarthritis varies throughout studies depending
on the research method. Some studies include self-reported osteoarthritis (usually from a
questionnaire), radiographic definitions of osteoarthritis (fully explained in Section 2.2.1),
and symptomatic osteoarthritis.
Cooper at al.[49] define hip osteoarthritis as:
“A clinical syndrome of failure of the joint accompanied by varying degrees of joint
pain, functional limitation, and reduced quality of life due to deterioration of articular
cartilage and involvement of other joint structures.”
According to the Centers for Disease Control and Prevention (CDC), the lifetime risk of
developing symptomatic hip osteoarthritis is 18.5% for men and 28.6% for women.[50, 51]
Globally, of the 291 most common conditions,[52] osteoarthritis of the hip and knee were
ranked as the 11th highest contributors to global disability and 38th highest in disability-
adjusted life years (DALYs) (a measure of overall disease burden, expressed as the number
of years lost due to ill-health, disability or early death).[53]
The latest global report mentions that the years lived with disability has increased from 10.5
million in 1990 to 17.1 million in 2010.[54] Cross et al. concluded that with the ageing of
the population throughout the world, it is important for health professions to prepare for
an exponential increase of people with osteoarthritis requiring health services. Strategies to
reduce hip and knee osteoarthritis through primary and secondary prevention programmes
will become increasingly important. Improvements in imaging technologies may allow for
the development and improvement of treatment strategies in early disease identification by
providing detailed assessments of the arthritic joint.
1.6.1 UK Prevalence Of Hip OA And Total Joint Replacement
Arthritis is the biggest cause of pain and disability in the UK.[55] In the UK total hip
replacements (THR) for symptomatic osteoarthritis have increased by nearly 200% from
1991 to 2006.[56] Between April 2003 and December 2013 there were a total of 620,400
primary hip replacements performed, principally for osteoarthritis (in 93%). The number of
revision operations during the same 10 year was 14,903.[57]
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According to data collection done by Arthritis Research UK based on data recorded in an
anonymised general practice database, the CiPCA dataset[58] 8.75 million people (33% of
the population aged 45 years and over) in the UK have sought treatment for osteoarthritis.
They go on to specify that 49% were women and 42% were men aged 75 years and over,
suggesting that women are more likely than men to have sought treatment, see Figure 1.11.
(a) People Who Sought Treatment (b) Consultation Prevalence
Figure 1.11: Estimated Number Of People In The UK Who Have Sought Treatment For
OA, By Gender And Age Group
Used From Arthritis Research UK Information Handbook
The estimated number of people in the UK, aged 45 and over who have sought treatment for
osteoarthritis for joint specific sites is summarised in Table 1.1. The highest percentage of
the population (18%) su↵ered from knee osteoarthritis, second highest was hip osteoarthritis
(8%).
Joint Percentage of Population (%) Estimated number (million)
Knee 18 4.7
Hip 8 2.1
Hand & Wrist 6 1.5
Two or more sites 7 1.7
Table 1.1: Commonality of OA in each joint site of people in the UK, aged 45 or over
It is important to get an understanding of how many people in the UK have sought treatments
for osteoarthritis of the hip, bearing in mind, however that hip osteoarthritis is challenging
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to define and diagnose,[59] and no single diagnostic test of set of clinical criteria have been
routinely used in clinical practice. 2.1 million people (8% of people aged 45 and over) were
diagnosed with having hip osteoarthritis. 16% were women and 11% were men aged 75 years
and over. As with non-specific joint osteoarthritis statistics, women were more likely to have
sought treatment for hip osteoarthritis than men[58] Figure 1.12.
(a) People Who Sought Treatment (b) Consultation Prevalence
Figure 1.12: Estimated Number Of People In The UK Who Have Sought Treatment,
Specifically For Hip OA, By Gender And Age Group
Used From Arthritis Research UK Information Handbook
Hip osteoarthritis is increasing in prevalence in many parts of the world since the disease
increases with the age of a population.[60] In Iceland it has been shown that radiographic
occurrence of hip osteoarthritis is 5-10% in the general population. The lifetime risk of
patients in the United States developing symptomatic hip osteoarthritis is estimated to be
25.3%.[50] Further studies indicate that 5-17% of adults have symptomatic osteoarthritis of
the knee and 9% have symptomatic osteoarthritis of the hip.[61]
Numerous population based radiographic prevalence studies for hip osteoarthritis have been
performed, see Table 1.2[62, 63]. There may be a number of reasons for the apparent
variations in osteoarthritis prevalence found in these investigations. Apart from the varying
symptoms, clinical examinations and subject history there may be variable radiographic
definitions used for hip osteoarthritis and subjective joint space width (JSW) measurements,
Kellgren And Lawrence (K&L) scoring depending on the individual radiologist. This makes
the comparison of prevalence rates of hip osteoarthritis between di↵erent ethnic groups and












































































































































































































































































































































































































































1.6.2 Risk Factors Of Hip Osteoarthritis
The pathogenesis of osteoarthritis is multifactorial. Prevalent risk factors for hip osteoarthri-
tis may include age, sex, previous joint injury, obesity, genetic predisposition, and mechanical
factors such as abnormal joint shape or malalignment.[64, 65] These risk factors could be
grouped into systemic risk factors (age, sex, ethnicity, genetic variables), local risk factors
(previous damage, muscle weakness, joint malalignment, increasing bone density) and load-
ing factors (obesity, joint injury, damaging physical activity), see Figure 1.13.
Having a multifactoral pathogenesis, osteoarthritis most likely develops from a combination
of systemic, local and loading factors. While systemic background factors may predispose
a risk of osteoarthritis, it is the local risk factors and mechanical loading factors that may
initiate the cascade of joint changes resulting in clinical osteoarthritis. Systemic factors
are not generally modifiable but (can, for instance, in extreme genetic phenotypes such as
stickler syndrome) give vital clues about the degeneration of joint function from component
failure. However, local factors and loading factors generally tend to be modifiable; therefore,
potentially intervening in these (diet, muscle strengthening, decrease of damaging physical
activity), at the right time, could reduce the risk, or could prolong the health of a hip joint.
Figure 1.13: Common Susceptibilities To OA
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1.6.3 Systemic Risk Factors
Age
It is widely proposed that ageing has a negative e↵ect on the ability to maintain a strong,
healthy hip joint. Many believe that the aged hip joint is less able to protect itself
from natural bio-mechanical stresses due to degenerative changes in the articular cartilage
surface or from acquired joint laxity (which leads to damage from incorrect loading). In a
large study of symptomatic osteoarthritis it was observed that the prevalence and incidence
of hip osteoarthritis increased sharply with age, particularly after 50, with a decline after
age 70.[66] Murphy et al. modelled a 25.3% likelihood of symptomatic hip osteoarthritis
development in at least one hip by the age of 85, even after adjusting for ethnicity, body
mass index (BMI), sex and previous hip injuries.[50]
Sex
The incidence of hip osteoarthritis increased with age, and women had higher rates than
men, especially after age 50 with a subsequent levelling-o↵ or decline in both sexes around
the age of 80. As previously mentioned, there is a sharp increase in prevalence of hip
osteoarthritis after the age of 45.[61, 54] Prevalence, incidence, and severity of osteoarthri-
tis are di↵erent in women than in men. Women are more likely than men to su↵er from
osteoarthritis.[67–70] A Canadian study determined that women were not only more likely
to develop osteoarthritis but had worse symptoms, greater disability and were less likely
to have undergone arthroplasty.[71]
The relationship of age and sex is shown in Figure 1.14. It shows that men start to slowly
loose bone mass at about 50 years of age and women begin to lose it much more rapidly
after 50 y/o. This is generally because 50 is the average age at which women go through
menopause. Menopause not only lessens and ceases their menstrual periods, but it reduces
their ovaries in size. This ceases the production of oestrogen, a hormone that is known to
promote osteoblastic activity and production of bone matrix.[72, 73] Promoting nutrition
high in calcium and vitamin D and regular weight-bearing exercises early in life (before
the age of 30) can maximise bone mass and reduce the risk of bone mass loss.
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Figure 1.14: Relationship Of Age Vs Bone Mass
Used From OpenStax, Under A Creative Commons Attribution License (4.0) c 
Ethnicity
Ethnicity (where access to orthopaedic surgery joint replacement is equivalent for all
groups) appears to influence osteoarthritis development.[74] For instance in a U.S. study
of ethnicity,[75] Caucasian subjects had 2-10 times higher THR rates than that of any
other ethnic group (African, Hispanic, Asian). Osteoarthritis was the main indicator for
THR. Another ethnicity study, carried out in Hawaii,[76] looked at subjects <50y/o and
>50y/o. Oishi et al. found a quite low rate of THR for all ethnic groups of Hawaii <50y/o
(Caucasian, Japanese, Chinese, Hawaiians, Filipino). Merx et al. studied how total hip
replacements rates vary for ethnically Caucasian people in comparison to African, His-
panic and Asian ethnicities in the USA, noting that THR rates varied between 50 and
130 procedures for every 100,000 inhabitants. High annual THR rates were also reported
for Scandinavian countries: from 100 to 125 cases per 100,000 inhabitants reported in
Norway,[77] Iceland,[62] Sweden[78] and in the Netherlands.[79] When looking at data-
sets from England,[80] Australia[81] and the west of Scotland,[82] corresponding rates of
THR were intermediate, between 65 and 90 per 100,000 inhabitants. In studies conducted
between 1988 and 1990, THR rates showed similar findings with between 82 and 105 cases
in Denmark,[83] 58 and 105 in Finland,[84] 50 and 105 in Canada[85] and 60 and 105
in Olmsted County (USA).[86] Primary osteoarthritis was the documented indication for




Probably the first mentions of an inheritance factor of osteoarthritis were in papers from
the early 1950’s where a team investigated families of patients with bony swellings that
develop in the joints closest to the end of the fingers and toes known as Heberden’s nodes.
Stecher et al. found the nodes to be twice as frequent in mothers and three times as
frequent in sisters of a↵ected women.[87–89] Since then, numerous studies were conducted
on individuals with generalised osteoarthritis and many suggested inheritance to be factor
of hip osteoarthritis development. In the late 1980’s a study showed that the prevalence
of primary hip osteoarthritis in siblings of individuals with primary osteoarthritis was
nearly three-fold higher, 8%, compared with 3.8% in controls.[90] The authors of follow
up studies concluded that there were strong genetic influences observed in “common hip
osteoarthritis” in both women and men.[91, 92] A population-based study looking at twin
sisters found a direct relationship between hip osteoarthritis and bone mineral density of
the femoral neck of the a↵ected side. The study demonstrated that a higher femoral neck
bone density was associated with the presence of ostephytes in the osteophytic a↵ected hip
joint. Suggesting that there may be common genes for osteoarthritis and bone formation.
1.6.4 Local Risk Factors
Obesity
The relationship of being obese or overweight and hip osteoarthritis is inconsistent, it
is believed that if it does exist, it is a weaker relationship than the one with knee
osteoarthritis.[93, 94] Nevertheless there is consistent evidence that increased hip loading
from obesity increases the risk of symptomatic hip osteoarthritis.[95] There was “moderate-
strong” increased risk of THR with indiduals who had a higher BMI.[96–98] A study of 239
men found significant likelihood of hip osteoarthritis development if the BMI was higher
than normal.[99] Another study of 134 women also found significant correlations between
overweight individuals and symptomatic hip osteoarthritis. A systematic review exam-
ined 13 studies of obesity/overweight as a risk factor for (hip and knee) osteoarthritis and
overwhelmingly demonstrated an increased risk for hip osteoarthritis with increasing BMI
rating (odds ratio (OR) ranged from 1.6 to 15.4).[100] This was consistent with previous
such reviews.[97] All studies reviewed by Richmond et al. and Lievense et al. showed





Numerous studies have show that there is a greater risk of hip joint osteoarthritis in
individuals who have su↵ered previous injuries to the area.[101, 102] Heliövaara et al.
found an association between previous joint damage and hip osteoarthritis after adjusting
for age and sex (OR=2.1, 95% confidence interval (CI) 1.4, 3.1).[95] This is particularly
the case in those who had su↵ered fractures or ligament injury. Previous joint damage
also includes previous operations that may have been carried out on the femoral head or
acetabular socket.
Sports & Physical Activity
Similar to the inconsistent evidence seen in obese individuals, conflicting results have been
produced in studies examining the relationship between sports and various physical activ-
ities and subsequent osteoarthritis development. Osteoarthritis of the hip joint was found
to occur significantly more often in football players than in controls.[103–105] Klunder et
al. did not identify football as a risk factor for knee osteoarthritis. Lau et al. identified
gymnastics as a risk factor for hip osteoarthritis in women but not in men. Interestingly,
running, kung fu and football were not identified as risk factors of osteoarthritis in other
studies.[102, 106] Vingaard et al. concluded that medium-high exposure to sports activ-
ity before 50 y/o increased the odds of hip osteoarthritis (OR=4.5, 95% CI 2.7, 7.6 and
OR=2.6, 95% CI 1.5, 4.5 respectively). They also identified track and field (OR=3.7, 95%
CI 1.1, 13.2) and racket sports (OR=3.3, 95% CI 1.2, 12.7) as sports associated with the
highest odds of hip osteoarthritis.[104] Lane et al. identified that recreational physical
activities performed by women who were highly physically active before menopause may
increase the risk of both radiographic and symptomatic hip osteoarthritis.[107] However,
another study[108] came to the conclusion that there was no association between regu-
lar sporting activity and risk for osteoarthritis. Overall, the mixed results found for any
association between sports and hip osteoarthritis were most likely due to the di↵erent
definitions of “sports related osteoarthritis”. Some studies evaluated a single sport or
sport type, while other examined all sports or amount and type of sport. This may have
resulted in the heterogeneity of the results. It has been reported that clinical decisions of
hip osteoarthritis are often not influenced by radiographic changes but pain and scoring




There is commonly held view among clinicians that there is a relationship between lower
extremity muscle weakness and hip osteoarthritis. However, there is far less literature
available about this relationship compared to that of knee osteoarthritis. It remains un-
clear if the same muscles a↵ected and the same muscle weakness seen in knee osteoarthritis
is evident in hip osteoarthritis. Loureiro et al. conducted a systematic review to evalu-
ate any potential evidence for muscular weaknesses as underlying mechanisms for hip
osteoarthritis.[111] The review included 13 cross-sectional studies evaluating lower ex-
tremity muscle strength, size and quality in individuals with hip osteoarthritis. Loureiro
et al. found there to be consistent evidence for muscle atrophy and muscle weakness in
the leg of the individual that was a↵ected and moderate evidence for smaller muscles
of the a↵ected leg in individuals with hip osteoarthritis compared to healthy controls.
Eight of the 13 studies reviewed by Loueriro et al. investigated muscle strength between
a↵ected and contralateral legs in people with hip osteoarthritis. Predominantly the great-
est reduction in muscle strength (in the a↵ected osteoarthritic leg) was seen for the hip
and knee flexors and extensors. Studies reported that individuals with hip osteoarthri-
tis have significantly lower abduction, adduction and flexion muscle strength compared
to controls.[112, 113] Consistent evidence reported reduced quadriceps muscle size in the
osteoarthritic leg compared to the quadriceps muscle size of the contralateral leg. Con-
versely, a number of studies found no di↵erence in muscle size between the a↵ected leg
and a healthy control leg.[114, 115, 112] Grimaldi et al. identified that the gluteus medius,
piriformis, and gluteus maximus (see Figure 1.4) were smaller in size in individuals with
advanced hip osteoarthritis compared to mild-stage hip osteoarthritis; thus, suggesting
that muscle volume may be associated with hip osteoarthritis. Two studies that looked
at muscle quality in hip osteoarthritis reported lower radiological muscle density in the
osteoarthritic leg.[113, 116]
Joint Malalignment
Joint alignment is very important for correct load distribution. Any changes from the
neutral alignment of the hip will undoubtedly a↵ect the load distribution and forces ap-
plied on the femoral head. The angle alignment of the femoral head is important for the
movement of an individual, see Figure 1.15. The normal inclination angle of the femoral
head is said to be between 120-130 degrees (coxa norma).[117] In the elderly it is generally
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closer to 130 degrees, and any increase beyond this results in coxa valga. However, if there
is a decrease below 120 degrees, it results in coxa vara. The angle of torsion is also an
important alignment; for individuals termed “normal” the angle is ranged between 12-20
degrees. If the angle is beyond 20 degrees, it is termed as anteversion; if the angle is below
12, degrees it is termed as retroversion.
Coxa profunda refers to a deep acetabular socket. On pelvic X-rays it is seen as the ac-
etabular fossa being medial to the ilioischial line. It should be di↵erentiated from protrusio
acetabuli, where the femoral head is seen additionally medial to the ilioischial line. Coxa
profunda is much more common in females.
Figure 1.15: Deformities Of The Hip Angle
Adapted From https://commons.wikimedia.org/wiki/File:Coxa-valga-norma-vara-000.png,
Under A Creative Commons Attribution-Share Alike 3.0 Unported License c 
In general, most structural changes may lead to malalignment of the hip joint which in turn
may lead to hip osteoarthritis. Some of which may include pistol-grip deformity,[118, 119]
tilt deformity,[120] and femoral anteversion.[121] Acetabular deformities, may include coxa
profunda, protrusio acetabuli[122] or retroversion.[123, 124]
Tönnis et al. reviewed studies carried out investigating the measurements of torsion.[121]
The team found 4 studies[125–128] that supported a hypothesis of anterversion creating a
predisposition of hip osteoarthritis, and 3 studies[129–131] that showed that it does not.
Following the review study, Tönnis et al. suggested that reduced femoral and acetabular
anteversion may result in hip osteoarthritis. Jacobsen et al. found that the presence of
hip dysplasia (a decrease in the center-edge angle) significantly influenced the likelyhood
of hip osteoarthritis.[132] Similar studies found a strong association between acetabular




Richmond et al. reviewed 9 studies investigating occupation as a potential risk factor for
hip osteoarthritis.[100] All 9 studies reported a significantly greater risk of developing hip
osteoarthritis in individuals with occupations involving physically demanding activities
such as heavy lifting, kneeling, climbing stairs and other highly physical demands. Lau et
al. found that climbing stairs increased the risk of osteoarthritis (OR=12.5, 95% CI 1.5,
104.3) in men and heavy lifting increased the risk of osteoarthritis in women (OR=2.4,
95% CI 1.1, 5.3).[102] In a similar study investigating prolonged and frequent heavy oc-
cupational lifting as a cause of hip osteoarthritis, Cogon et al. found no comparable
association among women but an association in men (men who regularly lifted weights
of >50kg for +10 years had an OR=3.2, 95% CI, 1.6, 6.5).[135] Studies have found that
due to the work that farmers do on a day to day basis, they have a high prevalence of hip
osteoarthritis.[136] The cross-sectional survey of Heliövaara et al. in individuals exposed
to 3 or more physical occupational stresses (lifting, stooping or the use of a vibrating
tool) found the adjusted odds ratio to be OR=2.4(95% CI 1.4, 3.8) for unilateral hip os-
teoarthritis and OR=2.8(95% CI 1.6, 4.7) for bilateral hip osteoarthritis.[95] The results
that Richmond et al. identified were consistent with previous reviews that investigated
how occupational activities negatively a↵ected the hip and increased the likelihood of hip
osteoarthritis development.[137, 138]
Both systemic and local risk factors contribute in part to the development of hip osteoarthri-
tis. The biomechanics of highly focal concentrations of load within parts of the hip joint and
have an e↵ect on contact areas such as the labrum and cartilage. When 2-4 times the body
weight is transferred through the proximal femur, the abnormal increase in body mass has a
predictable e↵ect on hip joint wear. Some diseases of the hip (perthes disease, developmental
dysplasia) may lead to premature wear. Femoacetabular impingement (FAI) is likely caused
by bone/joint adaptation to high specific loading patterns, for example, certain sports (foot-
ball) during adolescence/skeletal growth. Intense sports or occupational factors may increase
the likelihood of hip damage in a number of di↵erent ways; there may be acetabular tears,
stress damage of subchondral bone or cartilage contusions.
26
Chapter 1
1.6.5 Symptoms, Signs And Diagnosis Of Hip Osteoarthritis
The principal symptom of clinically relevant hip osteoarthritis is pain.[108] This is typically
felt deep in the groin but may be felt over a wide area including the lateral thigh and
buttock, anterior thigh and even knee. Pain is initially felt on walking, but in advanced
cases often even occurs at rest and at night. Sti↵ness is common in patients and they may
have di culty doing routine tasks, such as bending over to put on socks and shoes. An
assessment of the walking profile, as well as passive and active moment of the hip joint,
is necessary. During clinical examination (particularly during bending, adduction, internal
rotation and maximal flexion) painful restrictions of both active and passive movements of
the hip are seen. Clinical diagnosis of hip osteoarthritis is usually based on a combination of
patient history and clinical examination, whereas staging/grading can be achieved through
radiography of the hip.
1.6.6 Pain Scores For Osteoarthritis Assessment
The establishment and evaluation of existing osteoarthritis related pain measures is key to
any pain score assessment. It is therefore important that all recommendations regarding
the measurement of pain, physical function, and joint structure of individuals with hip
osteoarthritis are conducted to a high standard using a recognised method. This makes it
essential to have a purpose-built multidimensional instrument with an ability to measure
clinically vital, patient-relevant symptoms in Osteoarthritis of the hip. Pain scores are an
important part of assessing whether osteopaths among other healthcare professionals are
improving the symptoms reported by their patients. The Oxford Hip Score (OHS) and the
Western Ontario and McMaster Universities (WOMAC) are examples of Patient Reported
Outcome Measure (PROM) assessing pain scores.
A PROM is as “a report coming directly from patients about how they feel or function in
relation to a health condition and its therapy without interpretation by healthcare profes-
sionals or anyone else”[139]. It directly establishes if treatment has improved a patient’s
symptoms, health and well-being, if patients are satisfied with their treatment as well as the
type of experience of care that patients received.
The OHS is a short report usually asking patients 12 questions about activities of daily living,
specifically designed to assess feedback on function and pain with patients undergoing hip
replacement surgery. It is reproducible and sensitive to clinically important patient changes.
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The WOMAC is a self-administered questionnaire consisting of 24 questions divided into 3
sections. Pain (5 questions), Sti↵ness (2 questions) and Physical function (17 Questions)
1.6.7 Investigation
Management algorithms are in widespread usage in primary care. The following have been
summarised for a clearer understanding.
These include:
(a) National Institute for Health and Clinical E↵ectiveness (NICE) CG177 and QS87
(b) Arthritis Alliance of Canada (AAC) and the Centre For E↵ective Practice Guidance
Tool (CFPC)
(c) Royal College of Surgeons Guideline (RCS)
(d) European League Against Rheumatism Guideline (EULAR)
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NICE CG177 and QS87
The Osteoarthritis Care And Management Clinical Guideline (2014) and the Osteoarthri-
tis Quality Standards (2015) mention that the results of X-rays and scans do not explain
symptoms or help when deciding about treatment. Avoiding imaging in osteoarthritis
reduces both potential harm from exposure to radiation from X-rays and costs of unnec-
essary imaging.
(a) NICE Clinical Guideline 177 (b) NICE Quality Standards 87




The Osteoarthritis Tool (2017) mentions that radiography does not reliably correlate with
symptoms, so suggest to reserve X-rays only for patients with advanced hip disease by
clinical examination.
Figure 1.17: CFPC Osteoarthritis Tool




The Pain Arising From The Hip In Adults (2017) mention that a record needs to be
kept of: history taking examination, and the if deemed necessary, plain anterioposterior
(AP) radiograph. Referral to secondary care particularly when hips are painful and sti↵,
interfering with activities of daily living, work or leisure and not responsive to conservative
measures, in which case a narrowed hip joint space is one of 4 clear indications for joint
replacement surgery.




The Recommendations For The Use Of Imaging In The Clinical Management Of Peripheral
Joint Osteoarthritis (2016) mention that imaging is not required [. . . ] in patients with
typical presentation of osteoarthritis.
Figure 1.19: EULAR Osteoarthritis Recommendations
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1.6.8 Treatment of OA
At present, there is no cure for osteoarthritis, it can only be managed with evidence-based
symptomatic management, divided into surgical, pharmacological and non-pharmacological
treatments. None of these treatments are perfect. Surgical intervention[140] as well as di-
rect articular cartilage repair[141] lead to improvements; whilst pharmacological treatments
are usually used for pain relief rather than prevention or cure. Aside from some experi-
mental drugs (such as strontium ranelate, now withdrawn due to safety concerns)[142] they
have not been shown to alter the progression of osteoarthritis.[143] Therefore, the need for
biomarkers that can predict osteoarthritis onset, monitor progression and evaluate response
to therapy is growing.[144] For any form of osteoarthritis, clinicians are reluctant to under-
take invasive surgical procedures such as THR. Clinicians aim to educate patients about
the disease and how to manage it. If the recommended lifestyle changes (weight loss and
exercise,[145] orthotics[146, 147] and pain medications[148]), do not alleviate the symptoms
of osteoarthritis, further (more invasive) treatments are suggested by a clinician.
1.6.9 Non-Steroidal Anti-Inflammatory Drugs
A pharmacological approach is always where clinicians start when dealing with osteoarthritis
complaints. However, it is always a challenge to decide which medications will provide a
particular patient with the greatest symptom relief and cause the least harm. Analgesics such
as Paracetamol and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) have been commonly
used as pharmacological treatment.[149] In 2006 a comparative e↵ectiveness review by Chou
et al. was published about analgesics use for osteoarthritis by the Agency for Healthcare
Research and Quality (AHRQ). Paracetamol (up to 4g/day) is an oral analgesic chosen
for mild to moderate pain in osteoarthritis.[150] NSAIDs decrease pain, inflammation, and
fever by blocking cyclo-oxygenase (COX) enzymes. They work by blocking di↵erent COX
isoenzymes (in particular COX1 and COX2). COX1 mediates the mucosal protection of
the gastrointestinal (GI) mucosa, protecting the area from acid and platelet aggregation.
COX2 mediates e↵ects on pain and inflammation in joints and muscles. By blocking COX2,
NSAIDs have been shown to reduce pain compared to placebo in patients with arthritis[151]
and lower back pain.[59] However, non-selective NSAIDs have also been noted to block COX1
enzymes causing GI bleeding.[152] The number of deaths in the United States estimated that
there were 3200 deaths annually in the 1990s due to the use of non-aspirin NSAIDs.[153]
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Topical NSAID are pain and inflammation relieving gels, creams, patches or sprays that
are applied directly to painful areas of the body. They work di↵erently from painkillers
that are taken orally and dissolve (releasing their ingredients) into the bloodstream. Oral
NSAIDs have been associated with potential gastrointestinal (GI), renal and cardiovascular
toxicity.[154, 155] Topical NSAIDs have been shown to be beneficial in reducing the likelihood
of an individual experiencing adverse e↵ects commonly associated with systemic therapy.
Studies have indicated that topical NSAIDs can achieve therapeutic concentration of drug
in localised tissues without raising serum levels, and thus potentially avoiding systemic
toxicity.[156, 157]
Other topical NSAID advantages[156, 158] include:
• Avoid first pass metabolism and GI tract variability common with drug delivery.
• Administered directly and immediately to local area of pain.
• Topical application may be more acceptable to patients, may increase adherence.
• Avoid drug-drug interactions or adverse reactions.
• Potentially decreased time to e cacy due to elimination of dosage titration.
Most disadvantages of topical NSAID applications are to do with local skin irritation,[159]
or the e↵ectiveness of drug molecules penetrating the skin (must be <500Da in order to
di↵use across the stratum corneum and penetrate to the painful site).[160]
1.6.10 Hip Injections
Injections into a joint are a very simple (but invasive) method to relieve pain in a joint; a
mild local anaesthetic and steroid mixture is prepared and injected into the area of pain.[161]
This is a short-term pain relief as the e↵ects of the local anaesthetic eventually dissipate;
the e↵ect of the steroid, however, is longer lasting. The anaesthetic is responsible for pain
relief, while the steroid is responsible for the commonly occurring inflammation associated
with arthritis.
A technique known as viscosupplementation has been developed, it uses hyaluronic acid
(HA), which is a molecule with rheostatic properties.[162] The aim of this treatment is to
lubricate the joint to relieve pain.[163] A study has shown modest improvements for os-
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teoarthritis patients, and profound improvements in patients <65 years with less severe
osteoarthritis development.[164] Experimental approaches include tanezumab (anti-nerve
growth factor therapy) and various modifies of the voltage-gated sodium channel (NAV)
1.9 pathway-hormone doubt is last on the safety of complete pain relief in osteoarthritis.
Nevertheless, a study has suggested that pharmaceutical pain relief for osteoarthritis is not
safe for long term use.[165] The e↵ects of pain relief injections may accelerate degenerative
changes as patients may not be able to realise when their joint is being overloaded. Pain
receptors are present naturally to prevent further damage of joints.[166]
1.6.11 Hip Arthroscopy
Hip arthroscopy or keyhole surgery as it is sometimes known is used to both diagnose and
treat problems with joints. It is usually a reasonable treatment for patients with movement
constrictions and undefined pain in the groin area. There are more than 1 million arthroscopy
operations annually worldwide.[167] The principle is to insert a probe (4.5mm in diameter)
into a joint under anaesthetic. A camera and computer attached to the probe allows the
clinician to directly observe the cartilage and bones of the joint in real-time. An accurate
assessment of the disease can be made, any loose bones can be removed, joint surfaces can
be cleaned, cartilage and ligaments could be trimmed (collected and removed) using the
attached surgical instruments.[168] This method is not necessarily an osteoarthritis cure; its
purpose is to relieve the pain and discomfort in a joint. Therefore, it is a procedure which
is most useful for younger patients and/or athletes[169] who are still physically very active.
This procedure will prolong their active lifestyle because a joint replacement would prevent
them from many physically demanding activities.
1.6.12 Femoacetabular Impingement
In the hip joint, arthroscopy is a procedure used to treat a condition known as FAI.[170]
Arthroscopy o↵ers a minimally invasive and e↵ective treatment for FAI. FAI occurs when
the AP aspect of the femur catches on the anterior aspect of the hip socket. FAI symptoms
include sti↵ness and pain in the groin, thigh and/or hip, (both at rest and during activity)
as well as an inability to flex the hip beyond a right angle. It is a condition in which excess
bone grows on the femur or acetabulum. This bone overgrowth or “bone spurs” usually grow
into irregular shapes, and because they no longer fit together perfectly, they cause abnormal
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contact, and begin to rub against each other. This can result in tears of the labrum. With
FAI, pain and rotational limitations develop over time as the join gets damaged.
Short-term outcomes of FAI were uniformly successful in previous studies.[171] However, it
is di cult to say that hip arthroscopy provides documented, reliable and prolonged relief
for FAI. When searching for long-term outcomes, hip arthroscopy has demonstrated statisti-
cally significant patient-related outcome improvements at minimum 5-year follow-ups.[172]
However, currently there is insu cient literature to support hip arthroscopy being superior
to open surgical techniques.
There are three recognised types of FAI: cam, pincer, and a combination of both cam and
pincer, see Figure 1.20.
Figure 1.20: Di↵erent Types Of Femoroacetabular Impingement
In Cam impingement the femoral head is no longer completely round; therefore it can no
longer rotate smoothly inside the acetabulum. Bone spurs on the edge of the femoral head
begins to grind with the cartilage inside the acetabulum. In Pincer impingement, the femoral
head is excessively covered by the acetabulum. This impingement interferes with the rim of
the joint socket and may result in both cartilage and labral tearing. In combined impinge-
ment, both cam and pincer type of changes are present at the same time.
Arthroscopy is used to treat FAI by reshaping the damaged area and removing excess bone
in Cam or Pincer type of FAI. The operation is carried out (under general anaesthesia)
by inserting an optical device (arthroscope) and a drilling instrument (burr) into the joint
through small incisions in the skin, see Figure 1.21. The leg is rotated and the femoral head
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is drawn 1-2cm[173] out of the socket onto an extension table so that both assessment and
treatment (smoothing out and reshaping excess bone growth) of the joint can begin.
Figure 1.21: Repairing FAI Using Hip Arthroscopy
Image Adapted From https://www.fairview.org/patient-education/40139 On 10th December 2017
FAI may lead to other problems, such as labral tears. The labrum is a strong, flexible
ring of cartilage attached to the inner part of the hip socket. When the labrum is torn,
symptoms included: pain, clicking or locking in the joint. If a labral tear has been identified
during arthroscopic surgery, it can also be treated by removing, cutting, shaving or heating
the tissue.[173] An anchor is implanted into the acetabulum and a suture ties the repaired
labrum to the anchor so that it can heal, see Figure 1.22.
Figure 1.22: Repairing Labral Tears Using Hip Arthroscopy
Image Adapted From https://www.fairview.org/patient-education/40135 On 10th December 2017
The removal of bone spurs improves joint mobility, increases the area of joint rotation and
removes painful constrictions. Correcting FAI can help prevent further damage, however, not
all of the damage can be entirely fixed using arthroscopic surgery, especially if the damage
has not been detected early and is severe. It is currently the best way to treat painful FAI.
Irrespective of which FAI type is being treated, there may be complications with both. Cam
lesion resection can prove to be di cult if the bone spur extends posteriorly, this may result
in both over and/or under-resection. Pincer abnormalities are di cult to treat because
acetabular trimming usually requires labral detachment and re-attachment, and this is a
very precise and technically demanding procedure.
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1.6.13 Hip Cell-Based Therapy
Cell-based therapy for cartilage repair has been developing rapidly. It has the potential
to o↵er a solution to the repair and regeneration of cartilage and alleviate the pain and
symptoms associated with osteoarthritis. The most common types of cell therapy treatments
are the use of chondrocytes and mesenchymal stem cells.
Autologous chondrocyte implantation/transplantation (ACI/ACT) first described by Brit-
tberg et al.[174] has been used in clinical practice with >15,000 patients already receiving this
treatment around the world.[175] ACI techniques have also shown successful outcomes in the
hip.[176] The ACI process consists of three steps. First, a sample (⇠200mg) of hip cartilage
tissue is collected (arthroscopic biopsy) from a healthy region of the joint. Then, enzymes are
used to remove the extracellular matrix and isolate the chondrocytes in order to be cultured
in vitro. Finally, when enough cells have been acquired, they are implanted into the damaged
zone of articular cartilage in another arthroscopy procedure. Since Brittberg et al. first per-
formed ACIs, there have been tremendous advances in the refinement of the technique, with
the most recent ACI procedures ensuring long-term cell maintenance and reduced surgical
times.[177] Clinical outcomes of long-term follow-ups were reported with ⇠90% achieving
good to excellent results.[178, 179] On the 4th October 2017, NICE made a recommendation
for ACI for treating symptomatic articular cartilage defects of the knee. This allowed ther-
apy to be administered within the National Health Service (NHS) (the result of many years
of pioneering work led by Professor James Richardson). Separately a commercial product
Carticel was initially approved by the Food And Drug Administration (FDA),[180] however,
it was suggested to not be used for general osteoarthritis treatment[181] because ACI is only
applicable to local cartilage defects surrounded by healthy cartilage. Osteoarthritis on the
other hand often a↵ects large areas of cartilage disturbing the homeostasis of an entire joint
(not a small local defect). If chondrocytes are implanted in this environment, they may
undermine the e cacy of the repair process and cause undesirable di↵erentiation or general
apoptosis.[182, 183] In 2016 the FDA approved Maci (based on Carticel) as the first product
that applies the process of tissue engineering to grow cells on sca↵olds using healthy cartilage
tissue from the patient’s own knee.[184]
Significant clinical safety issues have not been reported using the ACI technique, however,
some of its requirements occasionally make it di cult to fulfil: there may be limited cell
numbers available, at least two surgical procedures are necessary, in vitro chondrocyte growth
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takes time, and the donor-site must be damaged when initially harvesting cells.[185, 186]
Mesenchymal stem cells (MSCs) have been suggested as a potential cell source to use instead
of a harvested cartilage biopsy. MSCs can be easily collected from numerous tissues around
the body such as bone marrow, adipose tissue and the synovial membrane. MSCs grow and
divide at a fast rate and are known to have immunosuppressive activities.[187–189] In several
clinical trials, bone marrow-derived MSCs have shown encouraging signs in the treatment
of knee osteoarthritis, significantly improving cartilage quality and decreasing pain but this
has not been investigated on large data sets.[190, 191]
1.6.14 Hip Osteotomy
Osteotomy, also commonly known as bone realignment, is a procedure that requires cutting
through a bone to create a surgical fracture to realign a hip/knee, and thus altering the
stresses of walking with the potential of pain relief,[192, 193], see Figure 1.23. Osteotomy
is highly invasive and is generally more successful for patients, who have an extensive range
of motion of the diseased joint before the operation. The procedure may delay the need for
total joint replacement for 5-10 years.[194] This is again a procedure which does not cure
osteoarthritis but delays the need for a THR.




1.6.15 Total Hip Replacement
When the pain of osteoarthritis becomes too unbearable and neither medications nor pre-
viously mentioned invasive treatments have helped the patients, the clinician uses clinical
assessment and imaging techniques to confirm suitability for joint replacement. This decision
is usually made when X-rays confirm joint space narrowing (JSN) reflecting severe cartilage
wear or severe JSN.[196] However, it should be noted that the correlation between X-ray
findings of osteoarthritis features and symptoms is poor, and often the clinical assessment
of an experienced surgeon is the key to patient selection. In a total hip replacement proce-
dure, the damaged bone of the femoral head and its cartilage is removed and replaced with
prosthetic components. The typical replacement components used for the prosthetics, see
Figure 1.24.
Figure 1.24: Individual Components Of A Total Hip Replacement, Merged Into An
Implant And Then Fitted Into A Hip
First the damaged femoral head is surgically removed, the femur is hollowed out in the centre
and a metallic femoral stem may be either cemented or “press fitted” into the hollow bone.
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A metallic or ceramic ball is attached to the upper section of the femoral stem in order to
replace the femoral head that was surgically removed. The damaged cartilage surface of the
acetabulum is ground down with specialised tools and is replaced with a metal socket. Screws
or cement hold the socket to the hipbone. A tough plastic or ceramic spacer is enclosed
between the new ball and the socket arrangement allowing for a smooth gliding surface and
rotation to mimic motion angles of the original femoral head.[197] The materials used have
evolved over time and di↵er depending on country, hospital and surgeon preference and/or
availability. There are advantages and disadvantages to the di↵erent components available
on the market.
Generally, THR is extremely e↵ective for symptom improvement and function restoration.
Feedback from a national survey conducted, known as Patient Reported Outcome Measures
(PROMs) for patient satisfaction “before and after a THR replacement” (taken from 93,881
hip replacement patients who filled in questionnaires between 2009 and 2012) reported that
85.6% of patients felt much better and could be more active postoperatively (in later years
such as 2015, 2016 and 2017 numbers higher than 90% were reported, and thus patient
satisfaction post THR replacement appears to be constantly increasing).
Following extensive research and patient studies, Arthritis Research UK claim that approx-
imately 80% of cemented hips last for 20 years.[198] Table 1.3 summarises the number of
hip replacements in England and Wales in 2011, it also includes revision surgeries. Of the
80,314 surgeries carried out in 2011 for THR, 11% were revision replacement surgeries.
Type of Joint Replacement Number Equivalent
Initial replacement 71,672 89
Revision replacement 18,641 11
Total 80,314 100
Table 1.3: Number Of THR Replacements In England And Wales In 2011
According to the latest annual report published by the National Joint Registry (NJR) the to-
tal number of primary hip replacements (majority due to osteoarthritis) performed continues
to increase with 87,733 performed in 2016, compared to 86,496 in 2015.[199]
A comprehensive summary of treatment strategies that have shown potential disease modi-
fying properties is included in Appendix A.
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Imaging Modalities In Assessment Of
Symptomatic Osteoarthritis
2.1 Background
Historically, a typical clinical assessment pathway for adults presenting with hip osteoarthri-
tis would have resembled the box below.
1. Persistent hip or groin pain
Particularly night pain
Functional limitation (reduced mobility, antalgia)
2. Primary care assessment
Clinical assessment of joint
Pain, range of joint motion (ROM)
Plain X-ray of the hips
3. Primary care non-surgical management
Analgesia
Aids (walking stick)
Physiotherapy and lifestyle/exercise advice
4. Secondary care musculoskeletal/orthopaedic assessment
For persisting symptoms and limitation despite therapy
[Plain X-ray of the hips to grade progression*]
5. Surgical decision making between orthopaedic team and patient
Selecting appropriate patients for total hip replacement (THR)
*denotes the steps now removed by current expert consensus guidelines[200]
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Hip osteoarthritis is a progressively degenerative disease of the joint and a leading cause of
pain and disability in older adults. Prevalent risk factors for hip OA include age, sex, pre-
vious joint injury, obesity, genetic predisposition, and mechanical factors such as abnormal
joint shape or alignment.[64, 65] There has been a 20% increase in cases of OA since 2002.[42]
Estimates from the US suggest that hip replacements for OA will increase 174% by 2030.[43]
A typical clinical assessment pathway for adults presenting with hip OA (for instance, the
2017 Royal College of Surgeons (RCS) “Pain Arising From The Hip In Adults” guide) ad-
vocates history of examinations taken and, if deemed necessary, plain AP radiograph and
referral onwards to secondary care, particularly when hips are painful and sti↵; interfering
with activities of daily living, work or leisure and not responsive to conservative measures.
Indeed, the RCS guide highlights a narrowed hip joint space as one of 4 clear indications
for joint replacement surgery. However, four recent guidelines (including one specifically on
OA imaging[200]) now recommend that medical practitioners avoid the use of imaging in
all forms of OA, basing the recommendations mainly on research showing that hip pain and
imaging findings are quite discordant.[201] Some recommendations are constructive, e.g. a
North American Osteoarthritis patient management tool which states that; “Radiography
does not reliably correlate with symptoms” (but does advocate X-ray only for patients with
advanced hip disease by clinical examination). Some limit the extent of their recommenda-
tion to “diagnosis”, such as the EULAR Osteoarthritis imaging guideline stating, “Imaging
is not required to make the diagnosis in patients with typical presentation of OA”. Others,
such as NICE (UK) Clinical guidelines and Quality, are hostile towards imaging of all forms
in osteoarthritis, referencing “[...] potential harm from exposure to radiation from X rays
and costs of unnecessary imaging [...]” and “the results of X rays and scans do not explain
symptoms or help when deciding about treatment.” Others, such as NICE (UK), highlight
harms and encourage imaging avoidance, see Table 2.1.
Many clinicians feel that X-rays and scans do help when deciding about treatment. Given
the very high success and satisfaction rate following THR, but the very high cost of this
definitive procedure ($13.4 billion in 2004 for all joint replacements in the US[202]), tools
are needed that can stratify patients with hip pain within a typical patient pathway. If a
cost-e↵ective imaging investigation could reassure patients and their clinicians that THR is
unlikely to be needed in the medium term, it would allow them to concentrate on e↵ective
lifestyle modification and self-management. By focusing on the poor correlation between
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imaging findings and pain, guideline writers may have missed where the utility of imaging
in osteoarthritis resides, in helping stratify patients who might benefit from referral to or-
thopaedic surgical services and reassuring those who are unlikely to require it in the near
future.
Guideline Recommendation
Pain arising from the Hip in Adults (2017)
Royal College of Surgeons Guideline (RCS)
History taking, examination, and then, if deemed
necessary, plain AP radiograph. Referral to
secondary care, particularly when hips are painful
and sti↵, interfering with activities of daily living,
work or leisure and not responsive to conservative
measures, in which case a narrowed hip joint space
is one of four clear indications for joint replacement
surgery.
Osteoarthritis care and management Clinical
Guideline(2014) and Osteoarthritis Quality
Standards (2015) National Institute for Health
and Clinical E↵ectiveness (NICE CG17 and QS87)
The results of X-rays and scans do not explain
symptoms or help when deciding about treatment.
Avoiding imaging in osteoarthritis reduces both
potential harm from exposure to radiation from
X-rays and costs of unnecessary imaging.
Osteoarthritis Tool (2017)
Arthritis Alliance of Canada/Centre for E↵ective
Practice Guidance Tool (AAC/CEP)
Radiography does not reliably correlate with
symptoms, so reserve X-ray only for patients
with advanced hip disease by clinical examination.
Recommendations for the use of imaging in
the clinical management of peripheral joint
osteoarthritis (2016)
European League Against Rheumatism Guideline
(EULAR)
Imaging is not required [. . . ] in patients with
typical presentation of osteoarthritis.
Table 2.1: Osteoarthritis Guidelines
Planar radiography has been the tool most studied in this capacity. The hazard ratio of
radiographic hip OA for incident THR over 11–28 years was 12.9 (95% CI 7.9–21), regardless
of symptoms.[203] The grade of radiographic hip OA at baseline was, by far, the strongest
predictor of clinical progression or progression to surgery over 7 years with the OR for
THR increasing from 6 (all-comers, irrespective of baseline pain) to 24 (95% CI 11–52)
in those having both pain and radiographic OA at baseline. Why has downplaying the
predictive value of radiological OA hip features become widespread?[109] It seems clear
that older patients will have hip pain for many reasons (trochanteric bursitis, soft tissue or
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referred pain) unrelated to radiographic appearances, and equally clear that some patients
will tolerate OA changes in the hips without needing surgery due to di↵ering pain perception
or patient/surgeon inclination.
2.2 Introduction
I started by scoping Osteoarthritis guidelines from the last 3 years (2014-2017) that were
based on valid systematic literature review (SLR), and that gave specific evidence-based
recommendations concerning the role of imaging in the management of hip osteoarthritis in
adults. My Population Intervention Comparator Outcome (PICO) components were Popula-
tion [in older adults], Intervention [does imaging], Comparator [compared with no imaging or
symptoms alone] and Outcome [have utility in the primary management of hip osteoarthritis,
in particular, the selection of patients to refer for total hip replacement surgery]. I sought
documents in the public domain that based practical recommendations concerning the use
of hip imaging on SLR, involved relevant expert consensus and were accredited. Five cur-
rent guideline documents met the criteria, Recommendations for the use of imaging in the
clinical management of peripheral joint osteoarthritis from the European League Against
Rheumatism (2016), Osteoarthritis Tool from the Arthritis Alliance of Canada/ Centre for
E↵ective Practice (2017), ‘Pain Arising from the hip in Adults’ (2017), from the Royal Col-
lege of Surgeons (RCS, 2017), Quality Standard QS87 (2015), and Osteoarthritis care and
management Clinical Guideline CG177 (2014) from NICE (2015). In total, 4 guidelines deter
clinicians from ordering radiographs for hip osteoarthritis. EULAR advise against imaging
any joint in a patient presenting with pain, namely, “Imaging is not required [. . . ] in pa-
tients with typical presentation of osteoarthritis”. This is also the position of NICE who add
that “the results of X rays and scans do not explain symptoms or help when deciding about
treatment” and comment that their recommendations “[. . . ] reduce both potential harm
from exposure to radiation from X rays and costs of unnecessary imaging [. . . ]”. While the
Osteoarthritis Tool states, “Radiography does not reliably correlate with symptoms,” the
guideline reserves X-ray only for patients with advanced hip disease by clinical examination.
In contrast, the 2017 RCS recommendations (2017) state “a plain AP radiograph of the
pelvis may be requested to confirm the diagnosis after history and examination” and advise
surgeons to consider total hip replacement in 4 instances, including when “there is narrowing
of the joint space on radiograph”. I investigated the strength of these recommendations by
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evaluating the clinical utility of hip pain and various imaging parameters in confirmatory
case finding (that referral for total hip replacement would be appropriate) and reassurance
(that surgical referral would be unnecessary).
2.2.1 Radiographic Features Of Hip Osteoarthritis
A joint with a recognised severe radiographic change is more likely to be painful than those
with a mild or no change at all.[204] Individuals who require THR for osteoarthritis have
strongly associated hip pain symptoms and radiological changes.[205] Individuals with radio-
logical signs of hip osteoarthritis have restricted hip movement,[206] confirming that function
is correlated with radiological osteoarthritis, see Figure 2.1.
Figure 2.1: Radiographic Features Of OA.
Image adapted from [207]
The four most common radiographic features of hip osteoarthritis, see Figure 2.2.
i) reduction of the space between the femoral head and acetabulum (<joint space width)
ii) visibly denser area of bone just under the cartilage of the joint (subchondral sclerosis)
iii) formation of a fluid-filled sac that extrudes from the joint (subchondral cyst formation)
iv) outgrowths of bone tissue forming around damaged joints (osteophytosis)
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Figure 2.2: Radiographic Features Of OA
Joint Space Narrowing
When the loss of cartilage in an individual with osteoarthritis begins, it is commonly focal
and dominates sites of heavy weight-bearing joints such as that of the hip. Focal thinning
of cartilage manifest by JSN is an important observation that radiologists look for to
di↵erentiate osteoarthritis from other arthropathies, such as rheumatoid arthritis.[208]
Subchondral Sclerosis
As osteoarthritis onset progresses, changes occur in the thickness of the cartilage which
lead to an increase in the transmission of forces of maximal stress on the subchondral bones
of a joint. These bones naturally respond by increasing local blood flow[208] and increase
bone density or thickness. However, basic research into OA mechanisms is highlighting
the fact that subchondral bone thickening may in facet precede overlying cartilage loss.
Trabecular microfractures may begin to occur creating a radiographically visibly denser
area of bone under the cartilage.
Subchondral Cyst Formation
Cysts typically occur in osteoarthritis but are also seen in other arthropathies as fluid-filled
sacs that extend from the joint. Radiographically they occur at sites of increased pressure
transmission and joint stress. It has been suggested that pressure induced intrusion of
synovial fluid may cause cystic lesion growth.[209, 210]
Osteophytosis
Osteophytes are outgrowths of bone that commonly occur at the margins of osteoarthritis
joints. They are clearly visible and can be easily identified by radiologists. The spurs
themselves are not painful, but collision with nearby structures such as periosteum, can
cause pain with movement.
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2.2.2 Methods Of Radiographic Assessment Of Hip Osteoarthritis
Radiographic osteoarthritis has been the preferred definition of incident osteoarthritis in the
majority of large cohort studies. Radiographic definitions are usually based on the Kellgren
and Lawrence (K&L) system which grades (on a score out of 0-4) the extent of radiographic
osteoarthritis, see Table 2.2.
K&L Score Classification Feature Description
0 None No radiographic features of osteoarthritis
1 Doubtful Possible JSN and osteophyte formation
2 Mild/Minor Definite osteophyte formation and/or JSN
3 Moderate Definite osteophytes, definite JSN, sclerosis, cysts and possible bony deformity
4 Severe Large osteophytes, marked JSN, severe sclerosis and definite bony deformity
Table 2.2: K&L Grading System
It scores no disease as zero, and as the numbers increase up to four, so does the subjective
worsening of the disease. The scoring is based on the presence of certain key severity fea-
tures, such as accumulation of osteophytes and the space between the femur and acetabulum
known as the joint space width.[211, 212] The anatomy of individuals may vary, therefore
relying solely on radiographic findings in osteoarthritis is not always ideal as they do not al-
ways correlate with clinical symptoms. Thus, some studies which use only the radiographic
definition of osteoarthritis may not include patients with clinical disease. Just as, solely
relying on radiographic findings is not recommended, one should not solely rely on clinical
symptoms. Incorporating qualitative radiographic techniques, as well as clinical joint ro-
tation analysis and pain identification are key for more accurate and reliable osteoarthritis
classification.
This K&L grading system continues to be used by researchers today. Criticisms of the
system are directed at the emphasis on the osteophyte, the subjective grades of severity
from normal to severe (0–4), and that the system is relatively insensitive to changes. There
are also concerns over inter and intra-observer variability, hence it is not used routinely in
clinical practice. A comprehensive study was carried out by Reijman et al. where the group
investigated seven di↵erent measures of hip osteoarthritis.[213] They came to the conclusion
that minimum joint space width (mJSW) demonstrated the highest measurable reliability.
Joint space width (JSW) is a useful measurement for the radiographic assessment of hip
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osteoarthritis thickness of articular cartilage. JSW measurement in standing assesses com-
pression (under load) of cartilage, and its material thickness.[214] Measurements of the
mJSW are taken at or close to the side of load transmission in a joint. It is defined as
the smallest measurable distance between the acetabulum and the femoral head.[215] The
distance should normally be 2–3mm.[216–218] If a smaller distance than 3mm is measured,
this is an indication of radiological osteoarthritis.
When studies involve radiographic investigations of the hip, there are certain technical con-
siderations such as accurate positioning and image acquisition orientation. The most com-
mon radiographic method is the AP view where the hip is internally rotated. Other views
such as the cross table or frog leg lateral views require the hip to be flexed and externally
rotated to ensure that the X-ray beam could be directed posteriorly. On the AP radiograph
both, the greater and lesser trochanter, should be clearly visible and defined; the greater
trochanter should also not overlap the femoral neck. There should not be excess external
or internal rotation as both may impact on JSW measurements. The Lesquesne’s[219] view
(patient is standing) with an assessment of JSW may be useful for early osteoarthritis iden-
tification. It is an oblique view of the acetabular edge, thus able to diagnose if osteoarthritis
is a↵ecting the anterior part of the hip joint. The Lesquesne’s view is also useful to measure
the femoral head’s anterior coverage.
When radiographs are acquired, patients may be either in a supine position or standing.
Theoretically, a standing radiograph may provide a more accurate estimation of cartilage
thickness because it realistically recreates the weight-bearing condition the hip is naturally
found in,[220] accurate measurements of hip JSW can be obtained on both supine and
standing radiographs.[221–223] An exception of JSW assessment is patients with hip dys-
plasia, where standing radiographs generally provides more accurate results.[224] Supine
radiographs have been shown to provide more accurate assessment of JSW in obese patients
because there is less abdominal pannus projecting over the hip joint limiting X-ray beam
penetration.[221] So the most appropriate scan position depends on the what is best for the
individual being assessed.
If the subject is supine, the feet should be internally rotated 15-20 degrees and the X-ray
beam should be perpendicular to the table and centred on the superior area of the symphysis
pubis. This positioning will generate enough force on joint to mimic weight-bearing.[225] It
49
Chapter 2
is not always easy to get patients to accurately lay with a 15-20 degree for the duration of
the entire scan, so assistive positioning devices are often used.[221] If the subject is standing
then both feet should be internally rotated by 10 degrees for the scan.[133]
Spine CT images can be used to create digital reconstructed radiographs (DRR) which are
very similar but subtly di↵erent from the standing 2-view plain radiographs used in routine
clinical practice; hence our cut-o↵ values of mJSW cannot be applied to ordinary radiographs.
This modality of imaging will be extensively studied in the methods section.
How well does mJSW predict THR?
Few studies have investigated the predictive validity of di↵erent metrics of hip mJSW for
clinical outcomes. Liu et al. investigated how well 3D mJSW, over time, predicted or was
associated with subsequent THR.[226] They noted that all JSW loss metrics were signifi-
cantly associated with THR within 48 months, demonstrating the strong predictive validity
of hip JSW change for subsequent THR. In other studies, however, radiographic mJSW has
been shown to vary significantly within the joint itself.[218] This in itself raised questions as
to exactly where JSW measurements should be made.
How well does mJSW predict pain?
Numerous studies and systematic reviews have been conducted to better understand how well
mJSW predicts pain, and if people with pain have a significant change in their mJSW.[227] In
a population-based investigation of 3595 participants, the presence of hip pain was associated
with mJSW.[213] In a separate population-based study with a similar number of participants
(3208), a mJSW of 2mm was significantly associated with self-reported pain over a period
of 12 months.[228] A study of 220 subjects with hip pain of  3months found an association
with a mJSW 2.5mm.[229] A study of 759 men (60-75 y/o) identified hip pain as associated
with a reduced mJSW.[230] In a cohort of 195 subjects, a mJSW of 2.5mm was predictive
of being put on a waiting list for joint replacement.[231] In a study of 224 subjects (>50 y/o)
with hip pain, a joint space of <2.5mm was also predictive of eventual THR.[232] Overall,
most studies that have been reviewed suggest that, in the general, population and in subjects
with hip pain, there is an association between reduced mJSW and THR, therefore a mJSW
of 2.5mm appears to be the accepted diagnostic level for mJSW.
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The Outcome Measures in Rheumatology (OMERACT) is an independent initiative of a
committee of health professionals interested in outcome measures in rheumatology. They
have been responsible for the development, validation and implementation of clinical and
radiographic outcome measures in osteoarthritis and other rheumatic diseases.
What does OMERACT say about mJSW?
The objective of the OARSI–OMERACT initiative[233] was:
“...to define a cut-o↵ evaluated in millimetres on plain X-rays above which a change
in JSW could be considered as relevant in patients with hip osteoarthritis...”
Table 2.3 summarises the consensus based on expert opinion of a panel of researchers after
reviewing the results of systematic literature searches. There was a broad consensus for
the cut-o↵ values of 0.22-0.78mm on plain X-rays above which a change in JSW could be
considered as relevant in patients with hip osteoarthritis. The committee also believe that the
results of JSW analysis should be expressed in a dichotomous variable (progressors yes/no).
Definition
1 Structural progression is optimally defined by plain radiological evaluation of JSW in millimeters.
2
The results of the analysis of JSW should be expressed in terms of a dichotomous variable
(progressors yes/no).
3 An absolute change in JSW over a predefined threshold is defining a progressor.
4
The threshold above which a change in JSW can be considered as relevant should be based
on the evaluation of the measurement error of the radiological technique.
5
The Bland and Altman technique [234] is the most appropriate one to evaluate the measurement
error of the radiological technique evaluating JSW.
6
The pilot study aimed at evaluating the measurement error should be designed to reflect the
di↵erent characteristics of the primary study in which the analysis of the radiological findings
will be based on (patient’s characteristics, centers characteristics, readers . . . ).
Table 2.3: OARSI–OMERACT Definition Of Relevant Structural Progression In Hip OA
51
Chapter 2
2.3 Medical Imaging Using Ionising Radiation
2.3.1 Plain X-Rays In The Evaluation Of Hip Osteoarthritis
X-rays of the hips for the evaluation of osteoarthritis include a standing AP pelvis view
and frog-leg views of the suspected hip joint. On plain X-ray evaluation of an osteoarthritis
joint, loss of the radiolucent cartilage results in JSN. However, it is also possible to get more
central wear, particularly in patients with deep sockets or protrusio acetabuli. Subchondral
sclerosis or an appearance of whitening of the subchondral bone is also often present in ra-
diographic images of osteoarthritis. Osteophytes, which reflect a regenerative process with
formation of fibrocartilaginous extensions at the joint margins, are common.[235] When os-
teoarthritis is identified on plain X-rays, it means that there is often substantial cartilage loss
and sometimes full-thickness cartilage loss with bone-on-bone contact. Early osteoarthritis
detection and identification are important in order to reduce the likelihood of progression
to the bone-on-bone contact stage, which is inevitably painful and associated with loss of
function.
2.3.2 Computed Tomography (CT)
Computed Tomography (CT) is a 3D X-ray absorptiometric measurement which provides the
distribution of linear attenuation coe cient in a thin cross-section of tissue.[236] CT relies
on a photon beam passing from an X-ray source, through a patient’s body and detected on
the other side by detectors, see Figure 2.3.
Figure 2.3: CT Beam Setup
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In a typical acquisition period 10-50 rotations of the X-ray tube are made around a patient.
Many di↵erent snapshot images are collected at di↵erent angles during one complete rota-
tion. If the photon beam passes through a dense material (bone), it senses a fair signal,
conversely, if the beam passes through air or tissues, the detector senses a strong signal (the
quantified measurement of ease with which a material is penetrated by a beam is known
as the attenuation coe cient), a computer then reconstructs all of the individual snapshot
images into a cross-sectional image of the internal bone/tissue information and converts it
into a set of images.
2.3.3 Multidetector Computed Tomography (MDCT)
Modern advances in multi-detector computed tomography (MDCT) have had a profound ef-
fect on imaging of bones and their adjoining muscles.[237] Machines which are regularly used
in hospitals these days have unparalleled spatial resolution and incredibly fast scanning times
making them ideally suited for the assessment of bone surfaces in both healthy and trauma
patients. Some can even be used to check the integrity of already implanted orthopaedic
hardware.[238] There are some very important basic concepts which must be understood
when understanding musculoskeletal imaging: Magnetic Resonance Imaging (MRI), see Sec-
tion 2.4.2 has superior contrast resolution compared to CT, but CT can directly image both
cortical and cancellous bone. CT has greater spatial resolution compared to MRI meaning
that very small structures and details can be studied in detail. MDCT scanners are so fast
that they can produce entire isometric (identical length, width, and depth image informa-
tion) musculoskeletal image data sets in a manner of seconds. Isotropic images can be made
(where all dimensions of the volume elements of an image are of the same size) allowing
for high-resolution images to be produced in any plane, even after the initial images have
been acquired.[239] A very significant downside to MDCT is the relatively high dose of radi-
ation emitted. Numerous studies, however, have suggested slight modifications in the data
acquisition process to reduce the overall dose, especially for paediatric patients.[240–242]
MDCT scanning systems, unlike older generation CT systems which generated a single
photon beam, actually generate multiple photon beams simultaneously; they are sensed by a
system of detectors after they pass through a patient’s body, ensuring that multiple slices will
be observed by a computer simultaneously.[243] This type of system gives absolute freedom
for a radiographer to adjust detector arrays as necessary; for example, increasing or reducing
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the slice thickness (as thin as 0.5mm). This also means that the X-ray beam could be used
more e ciently than older CT systems, see Figure 2.4, reducing the radiation dose and
increasing the axis or rotation and therefore capturing more slices in with less radioactive
damage to cells.[244]
Figure 2.4: E cient Use Of X-ray Beam By Increasing Slices And Reducing The
Radiation Dose Compared To The Same Number Of Slices Acquired Using Plain CT
2.3.4 Hounsfield Units
A computer that is attached to the scanning system generates MDCT image data sets, the
images produce various attenuation values of tissues, and these values are measured in what






The HU value for any material is defined by Equation 2.1[245]
Where HUs = The HU value for substance, s
µs = Linear attenuation coe cient for substance, s
µw = Linear attenuation coe cient for water, w
Air, which has very low density, has extremely low HU values. Tissues such as fat and
muscles have intermediate values of density and therefore intermediate HU values. Bone
has a very high density and therefore it has high HU values. Air measures -400 to -600
HU. Intermediate tissue like muscle has typical values of 40 to 80 HU. Fat (less dense than
muscle) has typical values of -60 to -100 HU. Cortical bone (outside of bone) typically has
values in the region of 400 to 1000 HU. Dense cortical bone has typical values of 1600 HU.
Cancellous bone (spongy inside of bone) has values of 100 to 300 HU.[246]
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2.3.5 Quantitative Computed Tomography (QCT)
Quantitative computed tomography (QCT) is a medical technique that is used to measure
the bone mineral density (BMD) using a standard CT scanner with a specific calibration
standard in order to convert the HU of the CT image to bone mineral density values.[247]
QCT enables the accurate quantification of 3D bone geometry and the accurate estimation
of volumetric bone mineral density (vBMD).[236] A typical QCT involves solid phantoms
(used for calibration) to be placed under the patient (usually attached to a belt) during the
CT image acquisition stage. Phantoms contain specifically chosen materials to represent
a variety of bone mineral densities. The most commonly used phantom materials, used
as a reference standard, are Calcium Hydroxyapatite (CaHAP) and Potassium Phosphate
(K2HPO4); however, it is common that each manufacturer has their own phantoms to fit
their own machines. QCT enables the application of finite element modelling (FEM), which
is a numerical engineering technique that enables a computational estimation of the e↵ects
on a bone when subjected to an external load. QCT, however, is not able to provide high-
spatial resolution images to quantify the trabecular bone microstructure due to the high
dose of radiation required to acquire such detail.[248]
2.3.6 Peripheral QCT
Peripheral quantitative compound tomography (pQCT) is a technique used to measure the
internal bone geometry. The X-ray source and detector rotate around a patient generat-
ing 1-2mm thick image data sets. Specific phantoms (usually hydroxyapatite) provides a
measurement of the vBMD: this ensures that it is independent of bone size. This method
provides a quantified assessment of the internal geometry of bone.[249] pQCT alone does
not measure BMD, but it can be used together with quantitative ultrasound as peripheral
methods of analysis.[250] It is not suitable for in-vivo measurements of the hip (only forearm
and tibia) but is highly useful for evaluating ex-vivo cadaveric hips.[251–256]
High resolution pQCT (HR-pQCT) is a technique which measures the vBMD, trabecular and
cortical micro-architecture of the distal radius and tibia with an isotropic resolution.[257]
HR-pQCT acquires patient images based on the same principles as standard QCT but it can
achieve a much higher resolution set of data; a disadvantage is that there is a smaller field of
view (an isotropic voxel size of 82µm).[258] This permits only the scanning of peripheral sites
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of bones. Previous research conducted by Nishiyama et al. 2013 has suggested that average
scans take 2.8 minutes to acquire an axial 9.02mm section in the only currently commercial
system available to the market (XtremeCT; Scanco Medical, Brüttisellen, Switzerland).[259]
2.3.7 CT Safety
Modern MDCT systems have significantly reduced patient radiation doses[260] compared to
the previous generation single-beam CT systems because they now have more e cient beams
and less scatter per slice when looking at the same parameters for a typical scan. However
what also needs to be considered when investigating radiation dose in the modern MDCT
systems is that they generally create more slices per scan with much more overlap than the
older generation systems: this essentially increases the dose.[261] After thorough investiga-
tion by the FDA, it was determined that a typical CT scan of a patients head produces
an e↵ective dose of 2.0 millisieverts (mSv), and a typical CT scan of a patients abdomen
produces an e↵ective dose of 8.0mSv.[262, 263] The time period for the equivalent e↵ective
dose from natural background radiation is 2.7 years, where they based the assumption of
an average “e↵ective dose” from natural background radiation to be 3mSv per year in the
United States. The values of 2mSv and 8mSv are comparable to 100-500 frontal-view chest
X-rays. Therefore, the FDA suggests that one standard CT examination with an e↵ective
dose of 8-10mSv could increase the possibility of fatal cancer of 1 in 2000 people.[264] Ded-
icated pQCT scanners use the old systems of CT technology (rotation and translation); it
is very slow to acquire image data, and each section takes about 1 minute to attain. The
radiation dose from central QCT is higher than Dual-Energy X-Ray Absorptiometry (DXA)
(e↵ective dose is 1 to 6mSv), however, this compares favourably when looking at something
like a lumbar spine radiograph (e↵ective dose is 700 to 1000mSv).[265] By using a low kV
radiation dose, the dose for QCT will be approximately 90mSv. A low kV value is important
in this case because most of the scattered radiation, which is generated at the start of an
X-ray beam, does not penetrate the body; at higher kV values, however, the scattered ra-
diation passing through the body contributes more to adverse e↵ects. Compared to central
QCT the dose from pQCT is extremely low (less than 0.5mSv).[266]
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2.4 Medical Imaging Using Non-Ionising Radiation
2.4.1 Dual X-Ray Absorptiometry (DXA)
Although classically a tool to diagnose osteoporosis and predict hip fracture, recent studies
pinpoint a role for structural measures by Dual X-Ray Absorptiometry (DXA)[267] and
density measures by DXA[268] in predicting hip OA and outcome. A DXA scan is most
commonly used to determine bone health. The test measures bone mass at the axial and
appendicular skeleton. It can be used to diagnose osteoporosis, determine chances of a
fracture occurring and measure a person’s response to ongoing osteoporosis treatment.[269]
DXA technology is the commonest in routine clinical use to measure BMD.[270] This imaging
technology is usually applied to the hip and spine.[271] It measures the attenuation of photons
of two di↵erent energies, allowing for the determination of whether it is bone or soft tissue;
photons with high energies are attenuated by bone, thus photons with low energies are
attenuated by soft tissues. Common features that DXA system printouts include are a
summary of patient demographics, image of the scanned skeletal site, a plot of patients’ age
versus BMD, and various numerical results. Correct positioning and data output of a DXA
scan, see Figure 2.5, the hip is internally rotated in order to make the lesser trochanter
not apparent to optimise the femoral neck analysis, the black lines are used for reference,
the large rectangle is used to show the region of interest and the small square is the Ward’s
triangle region of interest.
Figure 2.5: Typical DXA results and interpretation. a) Dual-energy X-ray-absorptiometry (DEXA)
of the left hip. b) T-score of –2.6 (black square) for the neck of the femoral bone (bone mineral density:
BMD). c) Results of DEXA showing BMD, T-score, Z-score and percentage compared to indicated reference
population (young adults, age match) at di↵erent regions of the left hip and mean values[272].
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2.4.2 Magnetic Resonance Imaging (MRI)
MRI measures the spatial distribution of specific nuclear spins of protons in the body. Elec-
trical signals from the spins are measured using precessional motion (change in the directional
axis of a rotating object) of the proton spins after getting excited by radio-frequency (RF)
pulses, which are irradiated in a constant static magnetic field. The electric signals in a
static magnetic field are known as nuclear magnetic resonance (NMR). NMR itself doesn’t
carry spatial information that is necessary to generate an image. Gradient coils are used to
generate spatial information. Pulsed electric currents drive these gradient coils in a strong
magnetic field. Such strong forces acting on the coils in this repetitive manner are responsi-
ble for the production of the stereo-typically loud sounds heard during an MRI scan. MRI is
able to evaluate both the structure and the thickness of articular cartilage. MRI can detect
large focal articular cartilage lesions that cannot be detected on plain films.[273, 274]
Figure 2.6: Graphic representation of FID and spin echo for a typical MRI scan. Spin
echo signals decay exponentially. T2 is the relaxation time and it represents the time
constant of this decay curve. The faster decay due to non-uniformities in the magnetic field
is known as the FID with a time constant of T2*
As Figure 2.6 shows in the graphical representation, there are two types of NMR signals
used in MRI: free induction decay (FID) and spin echo.[275] FID is produced by one RF
pulse, it decays with a time constant T2*. At a specific echo time (TE), TE/2 after the
second RF pulse, the spin echo signal is observed, its signal decays with a time constant T2.
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The most important parameters of MRI are the proton spin relaxation times, the convention
used are: T1, T2 and T2*.
T1 is the longitudinal relaxation time, this is the duration that it takes the nuclear
spins to return to a thermal equilibrium post RF pulse irradiation. T1 is used to
visualise the degree of saturation of the NMR signal. Equilibrium magnetisation is
reinstated by T1 relaxation, it happens quickly for fat but more slowly for water.[276]
T2 is the transverse relaxation time, this is the lifetime of spin echo signal. T2 is used
to distinguish normal tissues from pathologic tissues because the “proton spins” of
pathological tissues generally have longer values of T2. When magnetisation is formed
in the transverse plane, it decays exponentially with T2 relaxation: again this happens
quickly for fat but more slowly for water.[276]
T2* is the decay rate of the FID signal. This means that tissues with a long T1 are
dark on T1-weighted images, and tissues with a long T2 appear bright on T2-weighted
images.
MRI can now be used to evaluate abrasions of the articular cartilage. Early studies have
suggested that the T1 and T2 weighted images are incredibly useful for the study of articular
cartilage degeneration in diseases like osteoarthritis.[277] A variation of classic MRI known
as magnetisation transfer contrast (MTC) imaging can separate articular cartilage from
adjacent joint fluid in its images by suppressing the signal produced from cartilage.[278, 279]
Driven equilibrium Fourier transform (DEFT) imaging has provided contrast between joint
fluid and the cartilage around it by improving the signal generated from the joint fluid,
rather than suppressing the signal from cartilage tissue as other technique do.[280] It has
been suggested that the signal intensity of articular cartilage not always be uniform due
to a number of internal factors which cannot always be controlled so the appearance of
articular cartilage is highly variable,[281, 282] it is, therefore, important to improve diagnostic
accuracy in order to reduce the risk of misdiagnoses.[283]
MRI has great potential to be more sensitive than both plain films and ultra-sonography in
the detection and grading of hip osteoarthritis. Of the current 3D imaging methods in use
today, MRI is used most commonly for hip osteoarthritis, as evidenced by scoring systems
such as the Hip Osteoarthritis MRI Scoring System (HOAMS) score, however, it is not as




MRI is a non-invasive system: it does not involve radiation (unlike CT). The main caution
is the e↵ect of the strong magnetic field on magnetic metal objects or potential implants a
patient might have, such as pacemakers, metallic clip, some artificial valves, and jewellery.
In some cases metal objects may be permitted, provided that they do not disrupt the image
of the area under investigation, but patients are very rarely permitted to MRI scans if they
have pacemakers, metal in eye, otic implants or cardiac defibrillators. There have been cases
when patients have died during an MRI examination,[285] so it is very important that care
is taken when deciding if a patient can and cannot have an MRI scan. Patients with tattoos
are also suggested to press icepacks onto the tattooed areas decreasing the potential for RF
heating.[286]
2.4.4 Ultrasound
Ultrasound is an established imaging technique that helps with early diagnosis and follow-up
of rheumatologic issues and conditions. Its relatively cheap cost to run means that many
more health centres can a↵ord to buy ultrasound machines than MRI machines and unlike
CT, no ionising radiation is involved, so no expensive radiation insulating rooms need to be
built.
Ultrasound imaging proves to be an essential initial point of investigation for real time
evaluation of many patients when they complain about internal discomfort. It is generally
the first tool doctors use to look at a patients soft tissues, blood flow assessment and bones
but cannot identify bone marrow edema.
Ultrasound images also known as sonograms are produced by sending a pulse of ultrasound,
typically in the frequency range of 1-18MHz into tissue using an ultrasound transducer. The
sound travels into the patients’ skin and reflects from parts of the tissue inside according
to the Doppler E↵ect; these signals travel back to the transducer and are recorded by a
computer to be displayed as an image to the operating clinician.
Current ultrasound systems are capable of resolving power of less than 0.1mm, this is not
even possible by MRI or CT.[287, 288] This high resolution is however not necessarily very
good at tissue penetration, therefore, ultrasound systems cannot image tissues at the same
depths MRI or CT are able to.
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Thinning of cartilage and the loss of joint space have been observed using ultrasound,[289,
290] however, such sonographs may be unreliable when small joints are being observed due to
transducer probe size limiting factors; therefore, the diagnostic accuracy relies heavily on the
experience of the sonographer and technology being used and must be studied with caution.
Weinrauch et al. recently described the use of ultrasound assisted hip arthroscopy (in more
than 700 procedures) as a simple and easily reproducible technique to manage central and
peripheral-compartment procedures. This reduced their need for fluoroscopy down to 2% of
the time.
Typical imaging features of interest in osteoarthritis are JSN, subchondral sclerosis and
subchondral cyst formation; therefore, radiographs still remain the standard for diagnosis,
however, this is not to say that ultrasound cannot be used to some extent, see Figure 2.7.
Ultrasound systems are better at quantifying cartilage loss in large joints such as the knees
and shoulders, which are close to the surface of the skin.
Figure 2.7: Hip Ultrasound Image
Image From https://images.radiopaedia.org/images/26775861/4b26dd0b950468b0892d710f1eb8b8_big_gallery.jpeg On 23rd June 2018
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2.5 Selecting An Imaging Technique For Hip OA Re-
search
When considering the di↵erent imaging systems available it is important to understand the
advantages and disadvantages of using each system both in a research and clinical sense. In
Table 2.4 the advantages and disadvantages of each of the techniques are evaluated. MDCT







1. With appropriate scanning parameters,
can produce extremely accurate
high-resolution images very fast.
2. Can evaluate internal derangement.
3. Compared to CT same acquisition in
shorter time (fewer motion artefacts).
1. High radiation dose.
2. Some imaging artefacts (although
better than single slice CT).










3. Measures bone geometry and strength.
4. Very detailed images of high resolution
quality (80µm).
1. Long scan times.
2. Sensitive to movement.
3. Used for peripheral sites (not hip).




1. Rapid scan time.
2. Low cost.
3. Low in ionising radiation.
4. Used in OA research mainly for hip
shape analysis.
1. Size dependent measurements
(low resolution).
2. Software and reference data changes.
3. Unable to quantify JSW, cortical




2. Generally painless and harmless.
3. Excellent imaging detail.
4. When necessary MRI contrast agents
(normally gadolinium) are less allergenic
than CT contrast agents (iodine-based).
1. Long scan times, di cult to lay
still for +30 minutes for patient.
2. Not suitable with metal implants.
3. Can cause heart pacemakers to
stop functioning.








2. Provides some basic bone density.
and some structural information.
3. Safe, portable equipment, easy to use.
4. Most inexpensive imaging system.
1. Di culty to compare the results
obtained with those acquired by X-ray.
2. Same images are hard to replicate.






*Commonly used for bone measurements




In this chapter, I will discus the methodology of three studies, the results of which will be
reported in detail in Chapter 4.
The studies are:
(a) The Age, Gene/Environment Susceptibility-Reykjavik (AGES) Study – a study to
predict THR and hip pain in women and men
(b) The 3D Printing Study – a study to visualise the cortical thickening in osteoarthritis
and how it relates to the whole joint structure
(c) The Mindways Study – a study to understand how osteoarthritis-prone parts of the
femoral head cortex change with age in women
3.1 Methods Of The AGES Study
3.1.1 AGES Study Hypothesis
Hypothesis 1: 2D imaging will have clinical utility in predicting hip replacement in those
with hip pain.
Hypothesis 2: The 3D distribution of cortical bone thickness around the proximal femur will




Given the strong association between radiographic osteoarthritis and clinically meaningful
outcomes (THR and radiological progression), I set out to apply modern 3D imaging methods
to discover any characteristic radiological osteoarthritis phenotype that may be associated
with subjects progressing to THR. I investigated the positive clinical utility of hip pain
and various imaging parameters in confirmatory case finding (for total hip replacement
referral) and negative clinical utility of imaging in reassurance (that surgical referral would be
unnecessary). Using a large, prospective, nested case-control study, I investigated standard
imaging measures (such as mJSW and osteoarthritis grade[291]) alongside 3D computed
tomography measures[292, 293] of osteoarthritis as well as their association with hip pain,
to evaluate how well structural measurements at the hip predict incident THR in a normal
representative ageing Icelandic population of older men and women.
3.1.3 Study Population
Participants were volunteers in the Age, Gene/Environment Susceptibility-Reykjavik Study
(AGES-Reykjavik study), a single-centre prospective population study of Icelandic women
and men, initiated in 2002. The AGES-Reykjavik study was designed to study how var-
ious risk factors, such as genetic susceptibility and gene/environment interaction a↵ected
disease and disability in older age. It was a multidisciplinary study that provided detailed
phenotypes of cardiovascular, musculoskeletal, and neurocognitive systems as well as an
examination of body composition. The AGES–Reykjavik sample is drawn from an estab-
lished population-based cohort, the Reykjavik Study. This cohort of men and women born
between 1907 and 1935 has been followed by the Icelandic Heart Association since 1967.
Further design and recruitment have been described in detail.[294]
“AGES–Reykjavik is based on three general hypotheses: first, that genetic variation
contributes to disease occurring in old age; second, that selected diseases common in
old age share genetic, behavioral, and environmental risk factors; and third, that better
classification of phenotypes based on multiple streams of data, including midlife his-
tory and subclinical disease, will further the exploration of how these risk factors are
associated with complex traits and diseases manifest late in life.”[294]
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Discharge records from all hospitals performing THR surgeries in Iceland were examined.
Cases were reviewed by a rheumatologist with expertise in osteoarthritis, who confirmed
from medical records that the operation was carried out for osteoarthritis only, see Figure
3.1. Baseline assessment was extensive, involving pelvic CT and included hip pain specific
(WOMAC Osteoarthritis Index) questions from the AGES-Reykjavik questionnaire which
included health history, lifestyle practices and medication survey.
Figure 3.1: Schematic Of AGES Study Subject Selection, Inclusion And Exclusion Criteria
During an average five-years of follow-up of 3133 participants (with baseline pelvic CT
scans between 2002 and 2006), 95 THR were reported. Of the 3133 participants, 2848
were excluded for the reason that they were not individuals who underwent future THR,
they also did not match as controls to those participants who did go on to have THR.
Using a random selection procedure, at least two controls were matched to each THR case
matched for calendar year of recruitment, sex and age. Finally, osteoarthritis cases were
arbitrarily split into atrophic and hypertrophic on the basis of their osteophyte count[2]
(<10) to examine whether imaging findings associated more with one type or another. All
participants provided written informed consent, and the study was approved (VSN 00-063)
by the National Bioethics Committee in Iceland as well as the Institutional Review Board
of the Intramural Research Program of the National Institute of Aging.
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The full protocol for this imaging sub-study was considered and approved by the Icelandic
Heart Association steering group. 21 of the case subjects were rejected: 18 subjects went
on to fracture their hip but not due to osteoarthritis, 2 subjects had incomplete scans and 1
subject had motion artefact in the femoral shaft and neck. After the 21 cases were rejected,
74 subjects remained (48 women and 26 men), with 90 THR sides (16 subjects had bilateral
THR). 6 of the control subjects were rejected: 4 subjects had motion artefact in the femoral
shaft and neck, 1 subject had an incomplete scan, 1 subject presented with an unreliable
phantom density value. After the 6 controls were rejected, 184 subjects remained (116 women
and 68 men).
Baseline assessment was extensive, involving pelvic CT and included hip pain specific ques-
tions from the AGES-Reykjavik questionnaire (which includes health history, lifestyle prac-
tices, a medication survey, and a food history including early-life diet and social aspects




Have you ever had pain in or around either hip joint, including the buttock,
groin or either side of the upper thigh, lasting at least one month?
HEALHP12
In the past 12 months, have you had pain in or around either hip joint, including
the buttock, groin or either side of the upper thigh, lasting at least one month?
Table 3.1: Hip Pain Questions
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3.1.4 CT Image Acquisition
CT images of hips were acquired in the supine position using a standard clinical CT system
(Somaton Sensation, Siemens Medical Systems, Germany). Scans were acquired using a
standardised protocol and encompassed the proximal femur from a level 1cm above the
acetabular margin to a level at least 3mm below the lesser trochanter. Scan settings: 120kVp,
140mAs, 1mm slice thickness, pitch=1, xy pixel dimension of 0.977mm and 512x512 matrix
in spiral reconstruction mode using standard kernel with a 50cm reconstruction field of view.
An experienced musculoskeletal radiologist (Thomas D. Turmezei (TDT)) blindly scored
the osteophyte load in 3D using the multiplanar reformatted images of the CT scans, using
published methods.[1] Multiplanar reformatting was used to make a mean intensity projec-
tion slab aligned symmetrically in the axial plane to a true sagittal plane through the pubic
symphysis, with coronal coverage of the anterior and posterior hip joint margins (Table 3.2).
Osteophyte score (excluding the reaction area & fovea)
0 0 – 4 (sum of osteophyte sector scores from severity mapping)*
1 5 – 9
2 10 – 19
3 >20
Subchondral cyst score (excluding the neck or pit area)
0 Everything but grade 1 (grade from severity mapping)*
1 Any grade 3
JSW score (number of sectors with score 3, JSW <1.5 mm)
0 0 – 1 sector (derived from severity mapping)*
1 2 – 3 sectors
2 4 – 5 sectors
3 6 – 7 sectors
CT composite score** CT grade Verbal interpretation of CT grade
0 – 2 None (0) No radiological osteoarthritis
3 – 4 Developing (1) Developing radiological osteoarthritis
5 – 7 Established (2) Established features of typical radiological osteoarthritis
*using the severity mapping of the proximal femur method; **CT composite score (0 – 7) obtained by summing osteophyte,
subchondral cyst and JSW contingents.
Table 3.2: Interpretation of CT feature severity mapping score-sheets described in
Turmezei et al. 2014, used to generate individual feature scores for CT composite score. CT
composite score itemised into three separate CT grades
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This resulted in a slab thickness in coronal depth that could be reviewed in the coronal plane
as an AP pelvic radiograph, see Figure 3.2.
Figure 3.2: Coronal Mean Intensity Projection Slab (Usually 6–8cm In Depth) Showing
The DRR Used For Minimum JSW Measurement And K&L Grading
The same radiologist blindly graded AP mean intensity projection reformatted images, DRR
of the CT data to score osteoarthritis in each hip according to the Kellgren and Lawrence
(K&L) score criteria, see (Table 2.2).
A magnification of up to 200%, see Figure 3.3, and a digital caliper tool was used to measure
the minimal superior joint space width (mJSW) in a PACS viewer (OsiriX DICOM viewer
software ( c Pixmeo Sarl; v.3.9.3 32-bit, http://www.pixmeo.com)).
Figure 3.3: Representative image (in this case a coronal single slice) to demonstrate the
location of mJSW measurement; the narrowest point by eye (to direct digital caliper
placement). Note all mJSW measurements in the study were taken from a single radiograph
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The weighted kappa statistics[1] of previous studies showed “almost perfect” intra-observer
K&L grading for TDT (0.84 95% CI 0.57-1.00) but only “substantial” inter-observer relia-
bility (0.63 95% CI 0.37-1.00), hence choosing a single radiologist in the present study.
“Cohen’s kappa statistic takes into account any disagreement there may be between
two raters, but not the degree of their disagreement. Weighted kappa statistic is used to
calculate using a predefined table of weights which measure the degree of disagreement
between any two raters, the higher the disagreement the higher their weight. A table
of weights should be a symmetric matrix with zeros in the main diagonal (i.e. where
there is agreement between the two judges) and positive values o↵ the main diagonal.
The farther apart are the judgements the higher the weights assigned.”[295]
3.1.5 Methods Of Computational Analysis
Computational anatomy is a set of imaging analysis techniques that model anatomical struc-
tures in radiologically acquired images as curves, surfaces, maps, and volumes by combining
them across subjects to create statistical feature maps.[296] When the statistical features are
collected, they can be spatially analysed to detect subtle changes associated with prognosis,
progression or treatment of conditions making it possible to visualise group di↵erences or
longitudinal changes as statistical maps.[297]
Computational analysis of image data acquired by CT is important in the assessment of
osteoarthritis.[292] As mentioned[251, 252, 298] in 2011 a distinctive technique was devel-
oped to estimate and map cortical thickness, mass and density of a proximal femur known
simply as CBM, it analyses CT data at multiple surface normal points. The technique
works by estimating a standardised CT attenuation value of cortical bone.[251, 252] Further
computational analysis techniques recently developed alongside engineers include statistical
deformation modelling (SDM),[299] statistical parametric mapping (SPM),[300, 301] and
Finite Element Modelling (FEM).[302] All of these techniques have the potential to deter-
mine thickness and biomechanics in osteoarthritis pathogenesis, therefore I selected these
techniques to analyse the AGES data from Iceland. The CBM technique developed at the
University of Cambridge, use clinical CT, with results validated (using cadaveric femurs)
against data from HR-QCT acquired at a resolution of 82 microns per pixel. This technique
has been noted to estimate individual cortical thickness measurements even in the clinically
relevant sub-millimetre range. As long as there is an appropriate population study of indi-
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viduals, as is the case with data from both the AGES and Mindways studies, SPM can be
used to visualise and, more importantly, quantify the magnitude and statistical significance
of di↵erences.[251] The technique can also be used to estimate the cortical bone mineral den-
sity (CBMD),[252] response to treatment with teriparatide[253] and denosumab,[303] and
has previously been applied to an investigation of patients who have fallen and fractured
their hip. In that study the technique showed significant regions of cortical bone thinning
in the hip that match fracture type.[254] The work conducted by[251] suggests that the
true cortical thickness tr is calculated by Equation 3.1; where tm is the measured in-plane
thickness, x1 is the trabecular bone, x2 is the cortical bone and a is the surface orientation
angle.
tr = tm cos a = (x1   x2) cos a (3.1)
This equation allowed Treece et al. to begin calculations of the CBM by plotting CT value
(HU) against distance (mm) to produce graphs, see Figure 3.4. Treece et al. explained
that the CT value along a line passing through the cortex, see Figure 3.4, is simulated by
blurring what is known as a “piece-wise constant density function” (with CT values of -1000,
1750 and 0) with a Gaussian kernel of standard deviation (SD) of 1mm.[251] The solid lines
show the underlying and blurred CT values, the dotted lines show a threshold of 600, and
the dashed lines show values half way between the appropriate CT baseline and the blurred
peak (50% relative threshold).
Figure 3.4: A Simulation Of The Cortical Imaging Process
Used From Figure 2[251]
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If we analyse Figure 3.4 further, the cortex in Figure 3.4a, is su ciently wide for thresh-
olding and the 50% relative threshold methods to work correctly. The threshold in Figure
3.4b, still gives approximately the correct thickness, but the 50% relative threshold method
overestimates. No values exceed the threshold in Figure 3.4c, and the 50% relative threshold
method now reports the width of the point spread function rather than that of the cortex.
In this Treece et al. presented a novel method for the estimation of cortical thickness using
CT data. In the cadaveric experiments they conducted using the MDCT (589µm/pixel res-
olution) method, which was able to produce unbiased estimates with an accuracy of 0.3mm.
Unlike previous computational estimations, this method is highly automated and produces,
on average, 17,000 independent thickness estimates over the proximal femur surface,[251]
Which can be displayed as colours painted onto the 3D rendered surface with an appropriate
scale, this can be seen in Figure 3.5.
Figure 3.5: Cortical Thickness Estimation Colour Map On A 3D Surface
Used From Figure 14[251]
I selected this fully developed technique for both the AGES and Mindways study data sets,
as it was the most up-to-date and e cient method known. The process can be summarised
into nine basic stages represented by Figure 3.6 and Table 3.3.
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Figure 3.6: The Nine Stages Of Cortical Thickness Analysis
Image Adapted From Figure 2[304]
Stage Process
1 Measurements are performed at every vertex in an approximate segmentation of a femur.
2 At each vertex, the CT data is sampled on a line passing through the cortex.
3 A model-based fit is used to estimate the cortical thickness, allowing for image blur.
4 The thickness is mapped back to the 3D surface as a colour (here blue is thick, pink is thin).
5 An average femur known as a canonical (red) is deformed to match the current femur (green).
6
Thickness estimates are transferred to the average femoral surface and a smoothing
algorithm is applied.
7
This process is repeated for all subjects, producing subject-specific thickness estimates
all mapped to the same average surface.
8
The data is analysed using statistical parametric mapping to obtain mean thickness
di↵erences between groups and also the significance of these di↵erences.
9 One femur can model multiple di↵erences between groups.
Table 3.3: Summary Of The Nine Stages For A Typical CBM Process
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3.1.6 3D Cortical Bone Mapping
CBM is a technique[251, 252, 298] that estimates the cortical thickness (CTh) at thousands
of locations distributed over the proximal femoral surface using the software tool Stradwin
(http://mi.eng.cam.ac.uk/~rwp/stradwin/). The CBM technique generates a segmen-
tation of the proximal femur represented by a triangular mesh of vertices. The CT data is
sampled, and a model that accounts for the imaging blur is fitted to the data minimising the
di↵erences between the blurred model and the data. This is repeated at all vertices of the
surface mesh, and the CTh can be visualised as a colour map on the femoral surface. The
CBM technique, for the AGES study in particular, see Figure 3.7, is e↵ective in ordinary
clinical CT data-sets like these (thickness accuracy to 0.3mm with a mean ±SD error of
0.01±0.58mm).[251]
Figure 3.7: CBM Schema Demonstrating Pathway And Methodology
To allow for a population-based analysis of the cortical changes, a point correspondence has
to be found between the surface maps of all femurs. A canonical proximal femur mesh is
deformably registered to achieve this. After registration, the closest point on an individual
subject mesh is found for each vertex in the canonical model, and the corresponding cortical
measurement is copied onto the canonical shape. This ensures that for each new femur, the
measurements can be related to the measurements on corresponding locations of all other
femurs. The location and magnitude of patches of CTh associated with future THR can
then be highlighted using SPM. To calibrate CT Hounsfield units to equivalent bone mineral
concentration for this study, all subjects lay on a calibration phantom (Image Analysis,
Columbia, KY, USA) containing four calibration cells for equivalent bone mineral, adipose
tissue and water concentrations. If CBMD or endocortical trabecular density (ECTD) are
required, an alternative, equally valid approach would be to calibrate the scanner once using
a phantom set (known as “asynchronous QCT”), a phantom would no longer be needed.
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3.1.7 Statistical Parametric Mapping
Hips di↵er from one another in shape and size; therefore, I needed to co-register all of
the subjects onto a single “average” or canonical femur. The use of shape, modes in the
general linear model (GLM), ensures that thicknesses are compared without the shape inter-
fering (see Appendix B). An existing canonical proximal right femur mesh was deformably
registered onto all surface meshes using a freely available in-house program called wxReg-
Surf (http://mi.eng.cam.ac.uk/~ahg/wxRegSurf/). Each proximal femur was spatially
re-aligned with a canonical right femur using locally a ne deformation as calculated by an
iterative closest-point registration algorithm.[299] For the left femur, the canonical mesh was
mirrored to allow for the correct correspondences. After registration, for each vertex in the
canonical model, the closest point on the target mesh was found, and the corresponding cor-
tical measurement was copied onto the canonical mesh, meaning there was correspondence
of measurement locations for all femurs. By examining corresponding points between THR
cases and controls, I could map, visualise and statistically test the di↵erences in cortical
thickness over the whole surface of the proximal femur.[305] Corresponding measurement
locations for each subjects lends itself to statistical testing in 3D using SPM. The data
was smoothed over the surface during this process. SPM displays di↵erences and their sig-
nificance visually with a colour map on the canonical femur to show specific statistically
significant regions of interest (ROI).
SPM was developed to compare data at multiple points in space and locate various regions
of statistical variations with its earliest applications in neuroimaging of the brain. Statistical
analyses on the femoral surface maps were performed using the SurfStat software package
in Matlab R2016b (MathsWork, Inc., 1984-2016). In my case, the SPM technique has been
adapted to perform statistical analysis of univariate and multivariate femoral surface data
using linear fixed e↵ect models and incorporating random field theory.[306] SPM involves
fitting a GLM to account for variability in cortical thickness in terms of experimental and
confounding e↵ects (see Appendix C ). The GLM allowed for variables: group (case/control),
age, sex, weight, height, size (shape mode 0), neck length (SM1), neck shaft angle (SM2)




Standard two-tailed T-testing across the cohort gave p-values at each measurement location
that were uncorrected for multiple comparisons. However, as essential for SPM, random field
theory delivered p-values corrected for these multiple comparisons, thereby controlling for
false positive results (type I errors).[307, 308] Both, the relative di↵erence and significance,
are presented simultaneously in my results, since those di↵erences, that were statistically
significant, are retained, and the remainder greyed out on the surface maps, see Figure
4.1. The primary outcome measure consists of the areas where cortical thickness di↵ers
between participants going on to THR and those who don’t. To test the association between
cortical thickness di↵erences and clinical outcome (THR), all measurement points that are
statistically significantly thicker (or less likely thinner) between groups are required. All sur-
face locations where di↵erence between groups occurs are averaged, to make a geographical
“patch”. An average thickness is calculated within the “patch” for each individual.
3.1.8 Statistical Methods
All statistical analyses were conducted using Matlab, JMP (v13.0 SAS Institute Inc., Cary,
NC,1989-2007) or Stata Statistical Software (v14.2 StataCorp, TX, 2015). The baseline
diagnostic/predictive measures tested were hip pain (positive answer to AGES codes HEAL-
HIP12 question, see Table 3.1), osteoarthritis grade (by 2D K&L manual scoring), mJSW
and 3D CTh in the patch. Structural measures were used in logistic regression to deter-
mine the OR for THR expressed per one SD increasing grade of K&L or decreasing mJSW
or increase in CTh with adjustment for age, sex, height, baseline pain, femur shape, and
following leave-one-out cross-validation (using Matlab). The area under the curve (AUC)
was used to assess the performance of the model, with relevant 95% CIs. JMP was used
to derive appropriate cut o↵ values from Receiver Operating Characteristic (ROC) curves
by minimising the Euclidian distances, “ROC and pAUC”.[309] Also, within JMP, nominal
logistic fit methods were used to examine the relationships between the various grades or
increasing structural/imaging evidence of osteoarthritis and hip pain. Contingency analy-
sis and the Clinical Utility index[310] was used to estimate the performance of diagnostic
cut o↵s in regard to imaging utility in individuals presenting with baseline pain (a typical
clinical pathway, “IVD performance v.12.0”[311] JMP Add-In). Associations were sought
between HEALHIP12 (irrespective of THR status) and baseline hip structure. Performance
of the various logistic regression models, including imaging performance with and without
hip pain, was compared in STATA using the roccomp command and chi-square analysis.
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3.2 Methods Of The 3D Printing Study
3.2.1 3D Printing Study Hypothesis
Hypothesis 3: The 3D printed model of the SPM osteoarthritis ROI result will help with the
understanding of OA disease features.
3.2.2 Background
Safe, non-invasive and detailed imaging deep of an individuals’ body to look at the bones
inside remains a challenge in modern biomedical imaging. Interpreting radiographic images,
if one does not come from a technical radiological background, may be di cult. Trying
to look for bone disease features in an individual is also challenging. Studying how this
individuals’ disease features compare to others in a population is even more of a challenge.
X-ray imaging gave us the ability to non-invasively view the skeleton, but this converted the
3D human body into a flat 2D image. Revolutionary advances in imaging technology with
the development of CT, MRI, MDCT etc imaging (see Chapter 2) not only gave us the ability
to see inside the human body in greater detail, but it once again gave us the possibility of
rendering and visualising it in virtual 3D. This transformation from 2D to 3D was hailed as
the next big step in medical imaging when it was introduced over the last few decades. A
typical detailed procedure to study bone uses CT images. This means that 100-300 sliced 2D
images are taken with a particular size/thickness and space covering a particular region (for
example, 300 images at 1mm intervals). A virtual 3D model can be built up from these layers
of 2D images. Although the new imaging technologies helped radiologists, clinicians and
patients better visualise/interpret the body, the human brain naturally processes physical
objects to give depth information, and thus “Virtual 3D” images are still just 2D images
with a simulation of the third dimension of depth.
A simulated, virtual image on a screen is not equivalent to the visual experience of a physical
3D object. Therefore 3D printing of anatomic models is the next advancement in medical
imaging.[312–315] Since the late 1980’s, additive manufacturing, rapid prototyping or 3D
printing (as it is now commonly known) has been expanding and gaining popularity.[316]
Traditionally it was not used in medical applications, but with the development of newer,
faster and more accurate technologies, it has entered the medical field. Medical applications
for 3D printing are rapidly expanding and are predicted to revolutionise health care.[313]
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Uses of 3D printing in medicine is generally divided into two viewpoints: actual and potential.
Actual uses of 3D printing include anatomical model fabrication, tailored prosthetics and
implants. Whereas potential uses of 3D printing may include tissue and organ fabrication,
pharmaceutical drug delivery and drug dosage.[317] The cost of a 3D printed model is a
fraction of what it would normally cost to order custom built models, with a quicker turn-
around time from order to delivery.[318]
3D printed models add the concept of “touch to comprehend”[319, 320] which combines
natural biocular vision with multisensory inputs of touch. In numerous studies, surveys that
surgeons completed about the utility of 3D models given to them before surgery concluded
that in all cases, the surgeons found the models to be helpful.[321–323] So I became interested
in 3D printing the femoral structure generated which displayed “average” or archetypal os-
teoarthritis features, see Figure 4.1, not only at full scale while representing disease features
in printed colour on this 3D printed model.
3.2.3 3D Printing Study
I realised that my results could be visualised on a flat 2D computer screen with a virtual
3D appearance but I felt that due to the complex structure of the anatomy of the femoral
head and acetabular bone interaction I couldn’t reliable visualise it virtually. In this study I
wanted to have a hands-on visualisation of how cortical thickening in osteoarthritis related
to functional anatomy. I utilised an anatomical hip joint model with attached labrum and
prosthetic ligaments. I then needed to visualise typical hip movements in the canonical
hip, particularly I was interested in the correspondence between the statistical significant
thickness printed on in colour and the 3D joint structure as a whole.So I decided to create a
3D printed model of the SPM surfstat output, in order to better understand and communicate
my findings from the AGES study in a more tangible, easy-to-understand format.
3.2.4 Principles Of 3D Printing
3D printing in radiology is the process of fabricating or “printing” an object that is depicted
on Digital Imaging and Communications in Medicine (DICOM) images acquired from a
typical radiological scan. In general, 3D printers do not yet accept DICOM images as they
are not yet able to generate the exact object that needs to be printed. As described in
the CBM process, see Figure 3.7, the 2D DICOM images are imported into Stradwin, and
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segmentation of the anatomy is performed to generate a 3D virtual computer model of
the anatomy of interest. After the SPM analysis script is run in Matlab, a new 3D image is
generated with ROIs (this was step 6). The file generated is still not readable by a 3D printer
because it needs an Standard Tessellation Language (STL) or a Virtual Reality Modeling
Language (VMRL), also known as a .wrl file (this is step 7 of the post CBM pathway). STL
files cannot be used to print colour 3D models[324], so I decided to write a Matlab script
(see Appendix D) to export my SPM surfstat generated image into a .wrl file that could be
easily read by the 3DPrint (see Figure 3.8).
A .wrl file is a plain text file that includes data specifying details, see Figure 3.8, such as
XYZ coordinates, colour per vertex, and coordinate indexes for a 3D model.
(a) XYZ Coordinates (b) Colour Per Vertex (c) Coordinate Index
Figure 3.8: 3D Image .wrl Script Output Generated
The .wrl file is then imported (as a 3D interactive image) into the 3D printer software
(3DPrint) to be checked and prepared for printing as seen on Figure 3.9
Figure 3.9: Output of .wrl File Export From Matlab Script For 3D Printing
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3.2.5 The 3D Printing Workflow
The workflow from image acquisition to 3D printed object (specifically for my 3D model) is
shown in Figure 3.10. Several important methodological steps, necessary supplies, temper-
atures, as well as times, are shown in this workflow.
Figure 3.10: 3D Printing Process Flowchart Representing The Work Plan Form Imaging
Data To 3D Printer Object
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3.2.6 The 3D Printer Hardware
Figure 3.11: ProJet 600Pro 3D Printer
Although there are many di↵erent types of 3D printers, I was limited to what the Adden-
brooke’s hospital Media Studio had which were either the Binder Jetting (colourful Plaster
of Paris models from fine powder) and Material Extrusion (single colour plastic extrusion)
type of 3D printers. Luckily, Binder Jetting 3D printing is exactly I needed because it is the
most accurate and easiest 3D printing process to produces truly multi-coloured and durable
printed models.
The 3D printer used for the printing process is the ProJet 600Pro (late 2015 version) manu-
factured by 3D Systems Inc., see Figure 3.11. The 600Pro is known as a “Binding Jetting”
printer, otherwise known as a powder ink jet 3D printer. It uses a print head to jet a liquid
binding agent onto a bed of fine powder. The printer incorporates professional 4-channel
cyan, magenta, yellow, and key (black) (CMYK) full-colour 3D printing capability for re-
alistically accurate and consistent colour model printing. The printer is fast and produces
high resolution 3D prints. It also uses eco-friendly, non-hazardous materials with zero liquid
waste. The printing process begins at 25 C and takes 2 hours and 20 minutes to complete.
The binding agent, which in my case needs to be in colour, selectively bonds the powder
wherever the nozzle deposits it. After a layer is completed, the nozzle moves up and more
powder is deposited for the new layer on top. This ensures that the model grows (from
bottom up) on the metal surface bed.
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3.2.7 3D Printing Supplies
Figure 3.12: ProJet Supplies Arrangement
In order to produce a 3D printed model there must be an adequate supply of VisiJet PXL
Binder cartridges, VisiJet PXL Core powder and Ink cartridges, see Figure 3.12.
The VisiJet PXL Binder cartridges, see Figure
3.13, are coloured liquids (blue, magenta, yellow,
black, clear) that are dispensed through a HP11
print head, see Figure 3.14b, and applied to the
VisiJet PXL Core material. The Binder is applied
to the edges of the model with a higher saturation
in order to create a stronger exterior part of the
model. The interior areas of the model are printed
with low Binder saturation. The Binder is applied
layer by layer from bottom to top as the model
grows. Figure 3.13: VisiJet PXL Binder
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There are five HP11 print cartridge heads and they are arranged as seen in Figure 3.14a.
These print heads are responsible for printing the pattern of the model by gently squirting
drops of the PXL Binder, see Figure 3.13, onto the PXL Core material, see Figure 3.15, in
order to form a structure.
(a) Ink Cartridge Arrangement (b) Individual Ink Cartridge
Figure 3.14: 3D Printer Ink Cartridges
Figure 3.15: VisiJet PXL Core
The VisiJet PXL Core is a powder type ma-
terial similar to plaster and is non-toxic, see
Figure 3.15. It is what makes the model
structure when a Binder liquid is added. Un-
like with other 3D printing processes, sup-
port structures are not necessary because
the model is supported by unbonded Core
powder from all sides. Before the printing
process can begin, a layer of Core material
needs to be smoothly spread on the build
bed. When the printing is finished, excess
Core material around the model needs to be vacuumed (the Core material not used can be
indefinitely re-used for the next print until there is no more Core material left). After the
model has printed, it needs to be left to set at 25 C for 1 hour and 30 minutes. Then it can
be removed from the printer and undergo cleaning, see Figure 3.16.
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3.2.8 3D Printed Object Cleaning
After the printing and drying process, the cleaning step involves vacuuming and blowing
o↵ any excess unbonded Core powder, see Figure 3.16a. When the majority of the excess
core powder has been removed, the model is moved to the fine cleaning area which blows o↵
remaining Core material using compressed air and various soft brushes, see Figure 3.16b.
After the cleaning process, the model needs to be left to dry at 25 C for a further 1 hour
and 30 minutes before it can undergo Cyanoacrylate infiltrant adhesive treatment.
(a) Model Cleaning Process (b) Fine Cleaning Process
Figure 3.16: Post 3D Printing Model Cleaning Process
3.2.9 3D Printed Object Treatment
Because the plaster-like Core materials are gener-
ally fragile, even after several heat drying treat-
ments, care must be taken when handling the
printed model to minimise the likelihood of dam-
age. This is where infiltrant treatment with
Cyanoacrylate infiltrant solution, see Figure 3.17,
is necessary as it gives the model additional
strength and durability to make it safer to han-
dle. The printed model is dipped into an open bath
of Cyanoacrylate infiltrant until it is fully covered,
then it is placed into an oven at 30–40 C for 2 hours
to ensure that the glue has set properly.
Figure 3.17: Cyanoacrylate Infiltrant
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3.3 Methods Of The Mindways Ageing Study
3.3.1 Hypothesis of Mindways Ageing Study
Hypothesis 4: Distribution of cortical bone in the femoral head will become “osteoarthritic”
with ageing which will manifest as regional “thickening”.
3.3.2 Background
Previous imaging studies have revealed decreases in proximal femoral bone strength and
cortical bone thinning in older adults compared to younger adults.[325, 326] However, in
osteoarthritis of the femoral head, cortical bone thickening is observed, paradoxically. Given
the relatively strong association between age related bone changes and cortical bone struc-
ture, particularly in women, see Section 1.6.3, I set out to investigate if regional femoral
cortical bone thickening was an inevitable consequence of ageing or only occurred in select
osteoarthritis-prone individuals. I applied the CBM technique, see Section 3.1.6, and quan-
titatively examined in detail, how the femoral head bone cortex changes with age. Using
data from a large cross-sectional cohort, I investigated standard imaging measures of cor-
tical bone thickness. I hypothesised that the region of femoral head patch generated by
CBM would generally thicken with age as part of an inevitable “wear” pattern a↵ecting the
overlying cartilage.
3.3.3 Study Population
The Mindways study (based on data collected by Mindways Software Inc. (Austin, TX,
USA)) is a cross-sectional study that recruited 630 Caucasian women aged 19-97 years (mean
47 ± 17SD) between 1998 and 2002 at 11 centres all across the USA, see Figure 3.18.




The 11 recruitment centres included AD (Decatur, Indiana), BERG (San Luis Obispo, Cali-
fornia), BH (Bar Harbor, Maine), CF (Cannon Falls, Minnesota), CU (Gold Beach, Oregon),
FR (Los Angeles, California), MA (Rochester, Minnesota), MD (Owensboro, Kentucky), MN
(Millinocket, Maine), RF (Skowhegan, Maine) and SCH (Schnectady, New York), see Figure
3.19.
(a) 11 Di↵erent Healthcare Centres (b) States Of Recruitment
Figure 3.19: Locations Of Mindways Study Data
The cohort included women having bone mineral density (BMD) assessments as part of
their standard clinical evaluation as well as some volunteers who desired an assessment.
Clinical QCT data from the femoral head down to the lesser trochanter was obtained using
the Mindways hydrogen dipotassium phosphate liquid calibration phantom (K2HPO4). The
data was collected for FDA (510k) approval (K030330) and was subject to Investigational
Review Board oversight. Of the 630, 11 subjects were excluded due to having incomplete
scans (in some cases due to the presence of metalwork). The final study number of subjects
was 619, aged 20-97 years (mean 47.7 ± 17.3SD) summarised in Figure 3.20.




Similar to the method of the CBM technique carried out for the AGES Study, see Section
3.1.6, cortical bone thickness measurements of each proximal femur were made using the
Stradwin software package. Using this software, the contours of the bone surfaces are semi-
automatically drawn on the QCT slices. These were then processed into a triangular surface
mesh on which the cortical measurements are performed. Samples were taken in the QCT
volume, perpendicular to the bone surface, resulting in a profile of the QCT values with an
inherent smoothness. By fitting a blurred model of the cortex to the data samples, Stradwin
was able to accurately estimate the cortical thickness (measured in mm).
3.3.5 Statistical Analysis
Using the CBM output file and the cortical thickness values for each subject that were
available, I was able to plot and analyse (using JMP Statistical Software, see Section 3.1.8)
how the cortical thickness average per vertex values as well as the mean cortical thickness in
the ROI varied with age. This would demonstrate the relationship and significant cortical
bone thickness changes with ageing.
I modelled the data using standard modelling (linear regression) but, because my data
was non-linear, I decided to continue my analysis using quadratic modelling (quadratic
regression) as the latter allows for di↵erent rates of change at di↵erent ages and the possibility




4.1 Results Of The AGES Study
Hypothesis 1: 2D imaging will have clinical utility in predicting hip replacement in those
with hip pain.
Hypothesis 2: The 3D distribution of cortical bone thickness around the proximal femur will
predict hip replacement in those with hip pain.
4.1.1 Predicting Total Hip Replacement
Patients were well matched at baseline, see Table 4.1. Approximately two thirds of the
study participants were female. The average age of participants was 74 years (±4.7 years).
Cases underwent THR 35.8 months (±23.7 months, range 1–96 months) after their baseline
CT scan. The presence of hip pain was a poor to marginal predictor of THR (AUC 0.70,
cross-validated 0.63). Only 45% (33/74) of patients destined for THR reported hip pain at
the time of their CT scan. Of those 33 THR cases, the number of days until replacement was
available for 30 people. As expected, those 30 with baseline pain underwent surgery earlier
(average 28.9 months ±25.2 months, p=0.04), then the 41 who developed symptoms later
(THR at 40.8 months ±21.4 months, p=0.04). Next, I assessed the additional discriminatory
ability of di↵erent imaging outcomes for THR. Adding any radiological measurement to
hip pain alone greatly enhanced the prediction of THR, see Table 4.2. Adding a simple
distance measure (2D mJSW) improved discrimination from 0.70 AUC to 0.80 (p=0.02).
mJSW was non-normally distributed with a positive skew in cases and controls, with zero
values common in those destined for THR. As expected a wider hip joint space (mJSW)



















































































































































































































































































































































































































































































































































































































































































AUC of 0.79 (OR 0.26 per SD thicker, 95%CI 0.2, 0.4) increasing to 0.80 with baseline
pain included, see Table 4.2. As K&L grades of the 2D radiograph increased, there was an
exponentially increasing OR for THR. The model including K&L gave an AUC of 0.87 (OR
6.30 per incremental K&L grade, 95%CI 4.0, 10.0), unchanged by including baseline pain.
K&L gave better discrimination than the more basic mJSW (0.87 vs 0.80 p=0.0056). Either
manual K&L grade or 3D CTh were the best, and interchangeable single discriminators
in those with hip pain (AUC 0.87 with K&L and 0.85 with CTh, p=0.29, see Table 4.2).
However, 2D K&L grading and 3D CTh seem to provide di↵erent information, as manifest
by excellent discrimination of THR from control seen in a model containing; pain, K&L
grade and 3D CTh (AUC=0.90). Di↵erences in baseline CTh between subjects who went on
to have THR and matched controls are displayed as a statistical di↵erence map with a colour
scale for the magnitude of the relative di↵erences (colour map, see Figure 4.1). Grey areas
are regions where there was no statistical significance between THR patients and controls.
Blue, yellow and orange areas demonstrate 35–70% thicker femoral head bone in the focal
areas. The average CTh from within the multi-coloured ROI, see Figure 4.1, was used for
further analysis, with values and SD, see Table 4.1.
Figure 4.1: SPM generated cortical thickness image showing a statistically significant
thickening circumferentially around the periarticular margin, with up to 70% thicker
(green/blue) cortical bone at baseline in subjects who went on to have THR
The model containing average CTh from this ROI (alongside age, sex, height) predicted
incident THR well (see Table 4.2), with an area under the receiver operating curve of 0.83
(OR 5 per SD thickening, 95%CI 3.2, 7.7). Adding baseline pain to the model increased AUC
slightly to 0.85. 3D osteophyte load[1] accounted for 25% of the variance, see Figure 4.2,
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in CTh within the ROI (CTh in ROI=1.2–0.01*Osteophyte load, p<0.0001, adj R2=0.25).
While osteophytes did not fully explain cortical thickening, THR prediction in ROC analysis
was the same whether 3D osteophyte load or CTh was modelled (AUC 0.83). Thinning of
the joint space was only weakly associated with cortical thickening in cases (not controls)
explaining 6% of the variance in CTh (CTh in ROI=1.4–0.05*mJSW, p=0.03, adj R2=0.06),
see Figure 4.3.







hip pain only 0.70 (0.62–0.78) 0.63 2.21 (1.68–2.91) - -
Joint Space Width (mJSW) 0.79 (0.72–0.86) 0.77 0.26 (0.17–0.39) - -
ihip pain + mJSW 0.80 (0.73–0.87) 0.78 - 5.75 0.0164
OA Score (K&L) 0.87 (0.81–0.92) 0.85 6.30 (3.96–9.99) - -
iihip pain + K&L 0.87 (0.82–0.93) 0.85 - 20.35 0.0000
Cortical Thickness (CTh) 0.83 (0.77–0.89) 0.81 5.00 (3.24–7.71) - -
iiihip pain + CTh 0.85 (0.79–0.91) 0.83 - 14.30 0.0002
hip pain + K&L + CTh 0.90 (0.85–0.95) 0.88 - 26.80 0.0000
ROC, Receiver operating characteristic; AUC, area under the curve; AUC*, cross validated area under the curve; OR, odds
ratio per standard deviation (SD); CTh, cortical thickness; mJSW, minimum joint space width; K&L, Kellgren and Lawrence
score;  2=chi-square test; i vs ii,  2=9.25, p=0.0024; i vs iii,  2=2.21, p=0.1375; ii vs iii,  2=0.48, p=0.4881.
Table 4.2: Predicting THR for OA within 3 years (±2yrs); using baseline hip pain alone
versus adding imaging tests (comparison of area under the ROC curve of various models)
Figure 4.2: Osteophyte load correlated with
cortical thickness for cases (R2=0.25) but did
not for controls (R2=0.04). CTh in ROI=1.2-
0.01*osteophyte load, p<0.0001, adj R2=0.25
Figure 4.3: JSW correlated with cortical thick-
ness for cases (R2=0.06) but did not for controls




Hip pain alone had a sensitivity for THR of 44.6% (33.8–55.9), specificity 89.7% (84.4–93.3),
with the associated predictive values (PPV 63.5% (49.9–75.2), NPV 80.1% (74.1–85.0) PLR
4.3 (2.6–7.1) NLR 0.6 (0.5–0.76). All imaging investigations ranged in clinical utility index
from good to excellent, see Table 4.3. I considered the utility of the RCS clinical pathway in
52 of these patients presenting with baseline hip pain to a clinician. By requesting imaging
and receiving a grading report of “definite osteoarthritis” (2D radiographic K&L score of
 2), the primary care physician would correctly identify 85% (28/33) who would go on to
require THR for osteoarthritis within 3 years and reassure 95% (18/19) that THR would not
be performed. In clinical practice, knowing that the patient K&L score is  2 is excellent for
confirmative case finding, the patient may be destined for THR (positive clinical utility index
0.82 (0.70, 0.94)), and good for screening, ruling out a patient who is unlikely to require a
THR (negative clinical utility index 0.74 (0.62, 0.87)).
Measure
(+radiographic)








































PPV, positive predictive value; NPV, negative predictive value; PLR, positive likelihood ratio; NLR, negative likelihood ratio;
CTh, cortical thickness; mJSW, minimum joint space width; K&L, Kellgren & Lawrence score; *for females by  1.2mm and
males  1.29mm; **for females by 1.24mm and males 1.73mm; ***outcome by a K&L grade of  2
Table 4.3: E↵ects of imaging in the osteoarthritis clinical pathway; prediction of total hip
replacement by di↵erent imaging modalities in 52 individuals presenting with hip pain
Even simple measures had clinical utility: a mJSW 1.24mm for women and 1.73mm for
men would correctly identify 76% (25/33) and reassure 89% (17/19). In individuals with a
CTh of  1.20mm for women and  1.29mm for men would correctly identify 82% (27/33)
and reassure 95% (18/19).
Shape modes Chapter 3 Section 3.1.7 did not predict THR (see Appendix E ).
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4.1.2 Results Predicting Hip Pain
Structural measures of osteoarthritis were all strongly associated with prevalent baseline hip
pain, and these results are given irrespective of whether the study participant underwent
a THR or not. Odds ratios of K&L grade for hip pain on the correct side increased with
increasing radiographic severity, see Figure 4.4 and Table 4.4. Moderate/Severe grading (50
hips) yielded an OR of 12.22 (6.00–25.46, p<0.0001) for prevalent “correct side” hip pain.
Minimum joint space width was associated with hip pain (Figure 3, OR 2.7 per SD narrowing
95%CI 1.6, 4.4). Similarly, CTh was associated with hip pain (OR 2.1 per SD thickening
95%CI 1.5, 3.1). Odds ratios of K&L grade for concurrent ipsilateral hip pain were appropri-
ate to damage severity, see Figure 4.4. With reference to “no osteoarthritis” (K&L grade 0),
the OR of concurrent hip pain, see Table 4.4. Similarly, CTh was associated with hip pain
(OR 2.1 per SD thickening 95%CI 1.5, 3.1) and mJSW, in particular being strongly associ-
ated with hip pain (OR 2.7 per SD narrowing 95%CI 1.6, 4.4). In addition, multiple linear
regression was calculated to predict mJSW based on age, sex and hip pain (replicating[327]).
A significant regression equation was found (F(3,454)=26.1 p<0.0001) with an R2 of 0.15.
Participants’ predicted mJSW was equal to 3.12mm–0.35(pain)-0.02(age)+0.22(sex) where
pain was coded as 1=yes, 2=no, age was measured in years and sex was coded as 1=male,
female=2. mJSW was 0.35mm thinner in those with hip pain, males had 0.22mm wider
mJSW than females.
Figure 4.4: Odds ratio for hip pain vs K&L score in terms of radiographic classification,
irrespective of whether the participant was destined for THR or not.
Doubtful (66 hips), Mild (45 hips), Moderate/Severe (50 hips)
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K&L Classification Number of Hips K&L Grade OR (95% CI) P Value
Doubtful 66 1 0.83⇤ (0.24–2.28) 0.7363
Mild 45 2 1.98⇤ (0.69–4.95) 0.1914
Moderate/Severe 50 3+4 12.22⇤ (6.00–25.46) <0.0001
Moderate⇤⇤⇤ 40 3 8.92 (4.10–19.42) <0.0001
Severe⇤⇤⇤ 10 4 50.78 (10.05–256.58) <0.0001
mJSW 458 – 2.68⇤⇤ (1.64–4.36) <0.0001
CTh 258 – 2.14⇤⇤ (1.46–3.12) <0.0001
*versus none **per SD narrowing (mJSW) or thickening (CTh) ***individual K&L grades
Table 4.4: Hip Pain Odds Ratio Data
Histograms, as seen in Figure 4.5, show the association between narrowed JSW and hip
pain (lower panel) irrespective of whether patients were destined for THR for osteoarthritis
(hashed, within lower histogram). The upper panel shows the usual distribution of mJSW
in patients without hip pain. Note the similar right skew distribution of mJSW in those who
had not yet developed hip pain at baseline but were destined for THR (hashed, upper).
Figure 4.5: JSW And Hip Pain Association Histograms
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4.2 Results Of The 3D Printing Study
Hypothesis 3: The 3D printed model of the SPM osteoarthritis ROI result will help with the
understanding of osteoarthritis disease features.
A 3D printed model allowed us to visualise how cortical thickening in osteoarthritis (observed
in the AGES study) related to functional anatomy. I was able to attach the 3D printed femur
model to an anatomical hip joint model with integrated labrum and prosthetic ligaments to
observe and study where the areas of cortical thickening may have occurred. This enabled us
to visualise complex geometries of hip joint anatomy to better understand the ROI of cortical
bone thickening. Valdecasas et al. concluded that physical models provide an optimal tool
for the understanding of anatomy.[328] I decided to combine the 3D printed SPM ROI model
with a multi-component acetabular/pelvic model to be used as an analogous visual aid.
4.2.1 3D Printed Femur
After the 3D printing process, see Chapter 3 Section 3.2, was completed, the printed model,
see Figure 4.6, was the result. A 3D hip joint model complete with ligaments was obtained,
see Figure 4.7.
(a) View From Above (b) Side View
Figure 4.6: 3D Printed Femur
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4.2.2 3D Hip Joint Model
The anatomical model was the 66fit Anatomical Life Size Human Hip Joint with flexible
artificial ligaments, see Figure 4.7. Because I did not need to connect the ligaments to the
femur of the 3D printed model (with the statistically significant OA ROI coloured surface
printed on), it was decided that they were to be removed in order to not obstruct the view
of the socket of the accetabulum. The plastic femur was removed to make way for the 3D
printed femur and the entire pelvis was attached to an existing skeleton model that was
present in the lab, the final arrangement of the model can be seen in Figure 4.8.
(a) View 1 (b) View 2
Figure 4.7: Anatomical Hip Joint Model With Attached Labrum And Ligaments
Images taken from http://www.66fit.co.uk/66fit-human-hip-joint-anatomical-model.html
Figure 4.8: Adapted Arrangement Of Pelvic Hip Joint Model
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4.2.3 Combining The 3D Printed Model With Hip Joint Model
Looking at the two models together and manipulating the printed femur at various angles
allowed me to visualise how cortical thickening in osteoarthritis related to functional anatomy
(Figure 4.9). As can be clearly seen, the blue areas of maximal (approx. 70%) thickening
correspond almost exactly with the superior contact surface of the accetabular/labral margin.
(a) Hip Joint Model (b) 3D Printed Femur Introduced
(c) 3D Printed Femur Inserted Into Hip Socket (d) Leg Parallel To Body
(e) Leg In Front Of Body (f) Leg Behind Body
Figure 4.9: Various Angles And Views Of The 3D Printed Femur And Hip Model
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4.3 Results Of The Mindways Ageing Study
Hypothesis 4: The distribution of cortical bone in the femoral head will become “osteo-
arthritic” with ageing which will manifest as regional “thickening”.
I wanted to investigate if cortical bone thickening is an inevitable consequence of ageing
or only in select osteoarthritis prone individuals. By using the JMP statistical software
package and implementing the statistical techniques, mentioned in Section 3.3.5, I was able
to produce the following results, see Figure 4.10.
Figure 4.10: Standard Linear Model Of Cortical Thickness Average By Age
Upper panel (blue) is average across whole femur and lower panel (red) is the change in the
osteoarthitic-specific ROI.
From this initial observation I found that the overal femoral CTh (average per vertex)
generally decreases as age increases, with a linear function of y = 1.89 0.0051⇥Age, an R2
value of 0.19 and a root mean square error (RMSE) value of 0.18. When comparing this to
the results of the mean thickness in ROI, I found that there was no significant change with
increasing age and a linear function of y = 0.43  0.0004⇥Age, an R2 value of 0.003 and a
RMSE value of 0.13.
However, as previously explained, my data is non-linear so quadratic modelling (quadratic
regression) would allow for a more accurate interpretation to see how di↵erent CTh mea-




Figure 4.11: Quadratic Model Of Cortical Thickness Average By Age
From the quadratic modelling I confirmed (as with standard linear modelling) that the CTh
average per vertex generally decreases as age increases, but there is a sharper decrease after
the age of 50 as expected (in-part due to menopause), see Section 1.6.3. I found a quadratic
function of y = 1.56+ 0.009⇥Age  0.0001⇥Age2, an R2 value of 0.242 and a RMSE value
of 0.18. When comparing this to the results of the mean thickness in ROI, I found that there
was generally no significant change with increasing age but a wider range of mean thickness in
ROI at 80+ years. It also had a quadratic function of y = 0.45 0.001⇥Age+0.000001⇥Age2,
an R2 value of 0.004 and a RMSE value of 0.13.
Using the JMP software package, I was able to select a specific subject and understand
what CTh average per vertex value and mean thickness in ROI value they had and visually
highlight it on the quadratic graph.
98
Chapter 4
As an example, I chose to investigate 3 subjects from a variety of areas around the graph:
The first subject was a 62 year old with remarkably average (1.61mm) femoral head CTh vs
age, yet had the highest (1.18mm) mean thickness in the OA-ROI vs age (Figure 4.12).
Figure 4.12: 62 Year Old Subject; CTh Average Per Vertex=1.61 And Mean ROI=1.18
CT data of this individual illustrates the focal thickening of the femoral head. So I would
classify this subject as one who is likely to develop clinical osteoarthritis in the future (Figure
4.13) with possible likelihood of requiring THR.
Figure 4.13: CT Data Of 62 Year Old Subject
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The second subject was a 66 year old who rhad the highest average (2.32mm) femoral head
CTh, yet had only slightly above average (0.60mm) mean thickness in ROI vs age (Figure
4.14). Therefore I consider that generalised cortical thickening is not invariably associated
with thickening in the OA-ROI.
Figure 4.14: 66 Year Old Subject; CTh Average Per Vertex=2.32 And Mean ROI=0.60
The third subject was a 26 year old with modestly elevated (1.89mm) femoral head CTh but
with very thickened (1.12mm) osteoarthritis ROI despite her young age (Figure 4.15). I
consider that the discovery of such focal thickening in the OA-prone regions, despite modest
overall cortical thickness could indicate a potential novel biomarker for very early OA.




If findings from this large population-based Icelandic prospective study are generalisable,
then imaging seems to be a vital part of the e↵ective management of patients presenting
with hip pain. Unlike reliance on patient symptoms alone, all imaging measures tested un-
equivocally predicted THR within 3 years for symptomatic osteoarthritis, irrespective of the
presence of baseline hip pain. By focusing on the poor correlation between imaging findings
and pain, guideline writers may have missed where the true utility of imaging in osteoarthri-
tis resides.I suggest that clinicians should adhere to the 2017 RCS recommendations which
allow judicious use of AP radiographs in adults with hip pain. Any disutility of imaging
findings among some individuals with structurally damaged joints who exhibit little pain
or can tolerate pain, or those other individuals with hip pain who have little radiographic
hip osteoarthritis (perhaps, because they have another reason for hip pain), can be borne
in mind by the referrer in receipt of the radiology report but are not a valid reason to alter
this recommendation.[201] AP radiographs are an e↵ective diagnostic tool and permit the
timely identification of those patients with symptoms who would benefit from surgical re-
ferral. My findings support the use of diagnostic imaging in the clinical pathway for adults
presenting with symptoms of hip osteoarthritis, in keeping with the 2017 ‘Pain arising from
the hip’ guidelines of the Royal College of Surgeons. My results do not support guidelines
which deter clinicians from requesting all forms of imaging in people with hip pain (such as
the NICE osteoarthritis guidelines, new EULAR imaging in osteoarthritis guideline and Os-
teoarthritis Patient Management tool of the Arthritis Alliance of Canada). In my study, any
radiographic indicator of osteoarthritis accurately discriminated patients destined for THR.
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Why has downplaying the predictive value of radiological osteoarthritis hip features become
widespread?[109] It seems clear that older patients will have hip pain for many reasons (e.g.
trochanteric bursitis, soft tissue or referred pain) unrelated to radiographic appearances,
and equally clear that some patients will tolerate osteoarthritis changes in the hips without
needing surgery, due to di↵ering pain perception or patient/surgeon inclination.
We found that 2D hip radiographs were diagnostically useful, and would appear to fulfil
the validity questions for a diagnostic test and Quantitative Imaging Biomarkers Alliance
(QIBA) criteria of an imaging biomarker for disease (evidence-based medicine toolbox,[329]
QIBA https://www.rsna.org/QIBA/). I found that 2D radiograph grade performed very
well in predicting the need for a surgical solution to hip pain (cross-validated AUC 0.88).
Hip pain alone was less predictive (AUC 0.63). Optimum performance came from a model
containing pain, 2D grading of osteoarthritis and 3D cortical thickness (AUC of 0.90). Many
factors determine the decision to refer to surgeons or to o↵er THR, but simple imaging find-
ings are a key component of the patient pathway. For patients presenting with hip pain
by WOMAC questioning in my study, a finding of definite radiological osteoarthritis would
allow their clinician to correctly predict 85% that were likely to undergo THR within an
average of 3 years. Conversely, only 15% of patients had THR without baseline radiolog-
ical osteoarthritis.I have no follow-up imaging to know the rapidity of structural changes
in those individuals, butIspeculate that they also would have developed radiographic os-
teoarthritis. Since THR is not performed in asymptomatic individuals, it is noteworthy that
more than half (41/74) of those who would undergo THR had no hip pain at baseline sug-
gesting relatively rapid development of symptoms from joints that already bear structural
hallmarks of significant osteoarthritic disease. A phenotype of hip osteoarthritis, before
end-stage joint failure and hip pain might exist, amenable to emerging therapies. In this
respect, my work adds further useful data; concerning the 3D features that typify painful
and surgically-destined osteoarthritis.
Irrespective of the underlying cause of osteoarthritis, the uniform and characteristic pheno-
type of femoral cortical thickening shown here was useful for predicting THR. Arbitrarily
splitting the imaging findings into “atrophic” (with no osteophytes) and “hypertrophic”
(with osteophytes), based on 3D osteophyte load,[2] made no di↵erence to the discrimi-
natory ability of cortical thickness for THR, indicating a unified “end-stage” phenotype of
osteoarthritis destined for surgery, and one that is clearly associated with pain in that hip. In
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osteoarthritis, cartilage is lost, osteophytes begin to form at the edge of the articular cartilage
and the subchondral bone plate underneath is thickened.[330] Coronal plane radiographs of
osteoarthritic individuals are characterised by narrowing of the hip joint space, osteophytes
and femoral head bone thickening (subchondral sclerosis). These classic disease features are
strong predictors of osteoarthritis progression and THR but require careful assessment and
formal reporting of plain radiographs of the hips, something that I have found is not always
done. Irrespective of whether the hips had become painful, 3D focal bone thickening was a
strong predictor of eventual THR (OR 5 for each SD thicker). The location of the charac-
teristic bone thickening, see Figure 3.7, strongly supports the “wear and repair” concept of
hip osteoarthritis, being prominent at the femoral contact area with the acetabular labrum,
a site of high contact pressure at the articular margin where osteophytes form. A crescent
of thickening occurred in areas normally loaded during sitting, standing and walking. JSN
explained only 5% of the variance in cortical thickness, and then only in patients destined
for THR. This suggests that mechanisms other than cartilage loss are at play in determining
the thickening observed. This adds to a growing literature highlighting the importance of
bone in osteoarthritis pathogenesis. Osteophytes only accounted for part of the relationship
between increasing CTh and worsening osteoarthritis grade R2=0.25.[293] Bone structure it-
self has become increasingly appreciated as integral to osteoarthritis pathogenesis,[331] with
biomarker analyses indicating a link between subchondral bone characteristics (known to be
thickened in osteoarthritis[330]) and overlying cartilage loss.[332] Bone changes are not only
seem at the final stage of the disease, but at the onset.[333] leading some to suggest that
cartilage damage could be initiated by abnormal subchondral bone.[334, 335] Marginal thick-
ening of subchondral bone is presumably multifactorial: possibly from nascent osteophytes,
excess loading on the joint itself due to the subject’s joint shape or a previous trauma. Stud-
ies are now warranted that look at whether such features are present in people many years
prior to developing clinical osteoarthritis; key questions are whether they potentially predict
osteoarthritis onset, track joint degradation or can be used to evaluate the e↵ectiveness of
therapy.[336]
A formally graded 2D image (K&L method) in place of my advanced 3D CT bone thickness
measure gave equivalent performance (AUC 0.85 vs AUC 0.87 p=0.49) for less radiation.
While I used digital radiographs from CT, plain AP radiographs (referred to in the NICE
2017 Hip Pain pathway) are nearly equivalent in routine clinical practice. Formal grad-
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ing of hip radiographs in clinical practice is essential to achieve this level of accuracy, but
such assessments are rarely done despite long-established validity, and I do question that
part of the RCS 2017 pathway which states that, “referral should be independent of the
radiographic grade of arthritis”. TDT audited radiology reports and found only 53% relia-
bility from non-graded reports in allowing primary care doctors to determine which patients
should be referred for orthopaedic surgery assessment, 4% with no comment at all, 10% of
reports that could have led to missed referral and 33% of reports that could have led to
inappropriate referral.[292] Since formal K&L grading can be time consuming,[337] I tested
a simple narrowest superior joint space width (mJSW) measure which takes moments using
any modern PACS reporting station. Indeed, change in mJSW is the FDA-approved, vali-
dated method for assessing disease progression;[338] I found mJSW highly predictive of THR
in symptomatic individuals (AUC 0.80 vs AUC 0.87 of formal K&L grading, p=0.002); I
propose that this measure could be used in clinical practice easily.[291] Unlike Dougados et.
al, whose patients were selected for a therapeutic trial, I found a robust association between
pain and mJSW,[327] although obviously there are many unmeasured reasons for JSW to
di↵er widely between individuals.[337] While semi-automated 3D bone mapping from CT
has no prerequisite for radiological expertise, nor for subjective assessment of CT images
(important due to high K&L intra and inter-observer variability[339, 340]). Radiation dose,
availability, processing steps and cost of CT will clearly favour 2D radiographs.
A full cross-sectional cohort study design for diagnostic accuracy (imaging predicting sur-
gery) was not feasible, which is a limitation.[341] ROC analysis in matched case-control
studies may necessitate adjustment for potentially confounding covariates,[342] but I used
standard unadjusted research methods. Given the fairly low absolute THR rate in the
whole cohort, from which my nested case-control study was derived, it is a future priority
(when su cient time has elapsed from recruitment) to select a further nested sample of all
patients presenting with baseline hip pain from which to gather imaging diagnostic accuracy
data.[341] I lack information from clinical examination of the hip in the participants and
a lack of data on patient surgical/conservative treatment preference. I used supine CT
images to create digital radiographs which are subtly di↵erent from the standing 2-view
plain radiographs used in routine clinical practice; hence, the cut-o↵ values of mJSW cannot
be applied to ordinary radiographs. Iceland has a very high prevalence (five-fold higher than
in southern Scandinavia) of radiological primary hip osteoarthritis, particularly noticeable
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for individuals younger than 70 years.[62] Hence, generalisability beyond Icelandic population
is unknown. However, this study was the validation of an original discovery made in a UK
cohort[29] so it is likely that the findings are robust at least to the UK and Iceland.
The research findings explain why simple planar radiological features of hip osteoarthritis
are important; they usefully reflect the underlying 3D mechanics of joint failure that I have
quantified using more complex CT methodology. In light of the findings and in agreement
with Royal College of Surgeon Hip pain management guidelines, I suggest that simple planar
imaging assessment for structural features of osteoarthritis in individuals with hip pain is
useful to confirm the diagnosis and determine suitability for onwards referral to secondary
care.
5.1 Conclusions Of The AGES Study
If findings from this large population-based Icelandic prospective study are generalisable,
then imaging is a vital component for patient stratification. Unlike reliance on patient
symptoms alone, all imaging measures tested unequivocally predicted THR within 3 years for
symptomatic osteoarthritis, irrespective of the presence of baseline hip pain. By focusing on
the poor correlation between imaging findings and pain, guideline writers have missed where
the true utility of imaging in osteoarthritis resides. I suggest that clinicians should adhere
to the 2017 RCS recommendations which allow judicious use of AP radiographs in adults
with hip pain. Any disutility of imaging findings among some individuals with structurally
damaged joints who exhibit little pain or can tolerate pain, or those other individuals with
hip pain who have little radiographic hip osteoarthritis (usually because they have another
reason for hip pain) can be borne in mind by the referrer in receipt of the radiology report
but are not a valid reason to alter this recommendation. AP radiographs are an e↵ective
diagnostic tool and permit the timely identification of those patients with symptoms who
would benefit from surgical referral.
Signs of osteoarthritis from an AP radiograph unequivocally predicted THR for osteoarthri-
tis, whether or not pain had become apparent, whereas hip pain alone was a poor to marginal
predictor (AUC 0.70). Using all available imaging parameters in patients with hip pain gave
excellent prediction (AUC 0.90). In a typical clinical pathway, knowing that the patient
had radiographic osteoarthritis was “excellent” for confirmatory case finding; i.e. the pa-
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tient may be destined for THR (positive clinical utility index 0.82 95%CI; 0.70, 0.94), and
“good” for screening; i.e. reassuring that the patient was unlikely to require a THR within
the coming years (negative clinical utility index 0.74; 0.62, 0.87). In agreement with RCS
guidance, the results of an AP radiograph in patients with hip pain would have permitted
accurate stratification of the need for referral for surgery from primary care. Formal grading
of simple AP radiographs by a radiologist was as e↵ective as novel 3D CT methods in disease
prediction.
5.2 Conclusions Of The 3D Printing Study
The 3D printed model of the SPM osteoarthritis ROI result from the AGES study helped
with the understanding of osteoarthritis disease features and allowed me to visualise how
cortical thickening in osteoarthritis related to functional anatomy. By attaching the 3D
printed femur model to an anatomical hip joint model I was able to observe and study where
and why the areas of cortical thickening may have occurred. Individual patient specific femur
models mapping in colour the area of the joint that varies (either in thickness or joint space
narrowing) compared to an average population could potentially be used as a visual aid to
plan the patients personalised osteoarthritis therapy (weight loss, exercise, pharmaceutical
intervention etc). Patients appreciate visualising what is happening in their joints and,
these 3D models may provide patients with an accessible and easy to understand view of
their anatomy and diagnosis.
5.3 Conclusions Of The Mindways Ageing Study
With the Mindways ageing study I was able to use the CBM technique to show generalised
cortical thinning with ageing, but complete preservation of the OA-specific ROI throughout
life. Some subjects had markedly elevated cortical thickness in the hip-OA specific 3D
mapped region, and I postulate that they are individuals who are likely to develop clinically
or even surgically relevant osteoarthritis.
At the start of this work, I aimed to establish phenotypes of hip structure that are predictive
of clinical and surgically-destined osteoarthritis as potential novel biomarkers.
My studies have confirmed, unequivocally that 2D imaging has clinical utility in predicting
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total hip replacement in those with hip pain. Future work in this field will be to sample
all patients with baseline WOMAC hip pain in the AGES cohort and follow them up, since
at present I only selected those destined for THR (see page 99 and [341]). The work also
re-established the strong relationship between OA imaging findings and prevalent hip pain.
I established that the cortical bone thickening osteoarthritic phenotype (first identified in a
UK cohort[29]), is very strongly predictive of incident THR in those with hip pain, and much
more predictive than relying on symptoms alone. Further work will need to identify whether
this holds true for younger populations, meaning that a long-term prospective study is needed
using CT, potentially recontacting the Mindways cohort patients as they age. Further work
will also need to use finite element modelling and other biomechanical approaches to confirm
my assertion that the thickening is the result of focal wear and repair mechanisms. Finally,
I provide strong evidence for the central role of subchondral thickening of the femoral head
in osteoarthritis evaluation and pathogenesis.
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Appendix A
Summary Of Osteoarthritis Treatment Strategies
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Appendix B
AGES Statistical Parametric Analysis Matlab Script
This Matlab script was written by Graham M Treece, adapted and commented by me for
the AGES dataset.
1 %% variables which control overall behaviour
2 pthresh = 0.05; % statistical threshold
3 blank nonsig = true; % grey or washed out colours
4 compact = 6;
5 absolute = false; % false = percent changes & true =
6 % absolute changes
7 cmap = 4;
8 do cbm = [1:4]; % thickness, mass, density,
9 % trabecular density (all)
10 %do cbm = [1]; % only thickness
11 %do cbm = [2]; % only mass
12 %do cbm = [3]; % only density
13 %do cbm = [4]; % only trabecular density
14
15 %% set up some limits for the colourbars in the plots for HIP PAIN
16 % if (absolute)
17 % thick clim1 = [ 0.3 0.1]; % cTh
18 % mass clim1 = [ 25 0]; % CMSD
19 % density clim1 = [ 40 0]; % CBMD
20 % trab clim1 = [ 60 25]; % ECTD
21 % else
22 % thick clim1 = [ 40 4]; % cTh
23 % mass clim1 = [ 40 4]; % CMSD
24 % density clim1 = [ 40 4]; % CBMD
25 % trab clim1 = [ 2454.9 2411.7]; % ECTD
26 % end
27
28 %% set up some limits for the colourbars in the plots
29 % if (absolute)
30 % thick clim1 = [0 0.45]; % cTh [0 0.45];
31 % mass clim1 = [ 20 60]; % CMSD [ 20 60];
32 % density clim1 = [ 40 110]; % CBMD [ 40 110];
33 % trab clim1 = [ 60 80]; % ECTD [ 60 80];
34 % else
35 % thick clim1 = [0 70]; % cTh [0 70];
36 % mass clim1 = [ 10 70]; % CMSD [ 10 70];
37 % density clim1 = [ 5 20]; % CBMD [ 5 20];
38 % trab clim1 = [ 40 80]; % ECTD [ 40 80];
39 % end
40
41 %% set up mean value colorbar limits and some unit variables
42 thick clim2 = [0 5];
43 mass clim2 = [0 600];
44 density clim2 = [0 1200];
45 trab clim2 = [0 350];
46 thick units = {'(mm)'};
47 mass units = {'(mg/cmˆ2)'};
48 density units = {'(mg/cmˆ3)'};
49 trab units = {'(mg/cmˆ3)'};
50 percent units = {'(%)'};
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51
52 %% load canonical
53 if ¬exist('avsurf')
54 avsurf = SurfStatReadSurf( 'canonical femur 5580.wrl' );
55 end
56
57 [file, id, ok, side, bmd a, bmd b, hu, inblur, outblur, bmd, replace, ...
age, replace age, sex, height, weight, hp, replace side, KL, JSW, ...
OP, m{1}, m{2}, m{3}, m{4}, m{5}, m{6}] = textread( 'details.txt', ...
['%s %f %f %s %f %f %f %f %f %f %s %f %f %s %f %f %f %s %f %f %f %f ...
%f %f %f %f %f'] );
58
59 %% remove any redundant values
60 ok = ok & (age 6= 1);
61 file = file(ok);
62 id = id(ok);
63 side = side(ok);
64 bmd a = bmd a(ok);
65 bmd b = bmd b(ok);
66 hu = hu(ok);
67 inblur = inblur(ok);
68 outblur = outblur(ok);
69 bmd = bmd(ok);
70 replace = replace(ok);
71 age = age(ok);
72 replace age = replace age(ok);
73 sex = sex(ok);
74 height = height(ok);
75 weight = weight(ok);
76 hp = hp(ok);
77 replace side = replace side(ok);
78 KL = KL(ok);
79 JSW = JSW(ok);
80 OP = OP(ok);
81 shape modes = 6;
82
83 for sm=1:shape modes
84 m{sm} = m{sm}(ok);
85 end
86
87 %% load CBM data
88 Y thickness = SurfStatReadData( strcat(file,'thickness.bin') );
89 Y trab = SurfStatReadData( strcat(file,'trab density.bin') );
90 Y density = SurfStatReadData( strcat(file,'density.bin') );
91
92 %% average over left and right if both exist
93 s=sort(unique(id));




98 n = find(id==s(i));
99 if (max(size(n))>1) pairs = pairs+1; end;
100
101 mY thickness(i,:) = mean(Y thickness(n,:),1);
102 mY trab(i,:) = mean(Y trab(n,:),1);
103 mY density(i,:) = mean(Y density(n,:),1);
104 mid(i) = id(n(1));
140
105 mbmd a(i) = bmd a(n(1));
106 mbmd b(i) = bmd b(n(1));
107 mhu(i) = mean(hu(n));
108 minb(i) = mean(inblur(n));
109 moutb(i) = mean(outblur(n));
110 mbmd(i) = mean(bmd(n));
111 mreplace(i) = replace(n(1));
112 mage(i) = age(n(1));
113 mrage(i) = replace age(n(1));
114 msex(i) = sex(n(1));
115 mheight(i) = height(n(1));
116 mweight(i) = weight(n(1));
117 mhp(i) = hp(n(1));
118 mKL(i) = mean(KL(n));
119 mJSW(i) = mean(JSW(n));
120 mOP(i) = mean(OP(n));
121
122 for j=1:shape modes




127 Y thickness = mY thickness;
128 Y trab = mY trab;
129 Y density = mY density;
130 id = mid';
131 bmd a = mbmd a';
132 bmd b = mbmd b';
133 hu = mhu';
134 inblur = minb';
135 outblur = moutb';
136 bmd = mbmd';
137 replace = mreplace';
138 age = mage';
139 replace age = mrage';
140 sex = msex';
141 height = mheight';
142 weight = mweight';
143 hp = mhp';
144 KL = mKL';
145 OP = mOP';
146 JSW = mJSW';
147
148 for s=1:shape modes
149 m{s} = msm{s}';
150 end
151
152 clear mY thickness mY trab mY density mid mbmd a mbmd b mhu minb moutb ...
mbmd mreplace mage mrage msex mheight mweight mhp mKL mOP mJSW msm;
153
154 % densities are mg/cmˆ3, mass in mg/cmˆ2
155 for i=1:size(Y density, 1)
156 Y density(i,:) = (Y density(i,:) bmd b(i))./bmd a(i);
157 Y trab(i,:) = (Y trab(i,:) bmd b(i))./bmd a(i);
158 Y mass(i,:) = 0.1*Y thickness(i,:).*Y density(i,:);
159 end
160
161 % get mean values across all subjects
141
162 meanthick = mean(Y thickness);
163 meandensity = mean(Y density);
164 meanmass = mean(Y mass);
165 meantrab = mean(Y trab);
166




171 % do statistics
172 Replace = term(replace);
173 Age = term(age);
174 Sex = term(sex);
175 Height = term(height);
176 Weight = term(weight);
177
178 % added for hip pain SPM
179 HP = term(hp);
180
181 for sm=1:shape modes





187 for i=do cbm
188 if (i==1)
189 Y = Y thickness;
190 figtext = {'CTh'};
191 if (absolute)
192 mY = 100*ones(size(meantrab));
193 units1 = thick units;
194 else
195 mY = meanthick;
196 units1 = percent units;
197 end
198 clim1 = thick clim1;
199 clim2 = thick clim2;
200 units2 = thick units;
201 meanY = meanthick;
202 elseif (i==2)
203 Y = Y mass;
204 figtext = {'CMSD'};
205 if (absolute)
206 mY = 100*ones(size(meantrab));
207 units1 = mass units;
208 else
209 mY = meanmass;
210 units1 = percent units;
211 end
212 clim1 = mass clim1;
213 clim2 = mass clim2;
214 units2 = mass units;
215 meanY = meanmass;
216 elseif (i==3)
217 Y = Y density;
218 figtext = {'CBMD'};
219 if (absolute)
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220 mY = 100*ones(size(meantrab));
221 units1 = density units
222 else
223 mY = meandensity;
224 units1 = percent units;
225 end
226 clim1 = density clim1;
227 clim2 = density clim2;
228 units2 = density units;
229 meanY = meandensity;
230 else
231 Y = Y trab;
232 figtext = {'ECTD'};
233 if (absolute)
234 mY = 100*ones(size(meantrab));
235 units1 = trab units;
236 else
237 mY = meantrab;
238 units1 = percent units;
239 end
240 clim1 = trab clim1;
241 clim2 = trab clim2;
242 units2 = trab units;




247 % Calculate the actual statistics
248 M0 = 1 + Age + Sex + Weight + Height + Mode{1} + Mode{2} + Mode{3} + ...
Mode{4} + Mode{5} + Mode{6};
249 slm0 = SurfStatLinMod(Y, M0, avsurf);
250 M = 1 + Replace + Age + Sex + Weight + Height + Mode{1} + Mode{2} + ...
Mode{3} + Mode{4} + Mode{5} + Mode{6};
251 slm = SurfStatLinMod(Y, M, avsurf);
252 slm = SurfStatF( slm, slm0 );
253 [ pval, peak, clus, clusid ] = SurfStatP( slm );
254 cluster(i,:) = clusid>0;
255 mean thickness(:,1) = mean(Y(:,cluster(i,:)),2);
256 pval.thresh = pthresh;
257
258
259 %% Tom Turmezei code snippet for ROI
260 %deliver a mask ROI for the analysis
261 AGESmaskROI = (clusid == 1);
262 n = size(Y,1);
263 ROI.mean = double(mean(Y(:,AGESmaskROI),2));
264 save('ROI.mat','ROI')
265
266 %% Significance Plot
267 figure(fig num); % in case it doesn't already exist
268 if ((max(size(clusid))==0) | | (min(pval.C)>pthresh))
269 close(fig num);
270 disp(strcat({'No significance for '}, figtext));




275 lab = strcat({'Significance of '}, figtext);
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276 SurfStatViewFig( pval, avsurf, lab, 'white', compact );
277 pos = get(fig num, 'Position');
278 pos(1:2) = [50 (i 1)*250];
279 set(fig num, 'Position', pos);
280 fig num = fig num+1;
281
282 % Percentage Difference Plot
283 figure(fig num);
284 if 1
285 lab = strcat(figtext, {' difference with THR '}, units1);
286 SurfStatViewDataFigMasked( 100*(slm.coef(3,:) slm.coef(2,:))./mY, ...
avsurf, lab, 'white', pval, clim1, blank nonsig, compact, cmap);
287 pos = get(fig num, 'Position');
288 pos(1:2) = [200 (i 1)*250];




293 fig num = fig num + 1;
294
295 % Mean Difference Plot
296 figure(fig num);
297 lab = strcat({'Mean '}, figtext, {' '}, units2);
298 SurfStatViewDataFig( meanY, avsurf, lab, 'white', compact, cmap );
299 SurfStatColLim(clim2);
300 pos = get(fig num, 'Position');
301 pos(1:2) = [200*3 (i 1)*250];
302 set(fig num, 'Position', pos);




AGES General Linear Model Analysis Matlab Script
This Matlab script was written by Graham M Treece, adapted and commented by me for
the AGES dataset.
1 % what sort of validation to do
2 cross validate = true;
3 include jsm = false;
4 include shape = false;
5
6 do pain = [0 0 0 1];
7 do kandl = [1 0 0 0];
8 do jsw = [0 1 0 0];
9 do cbm = [0 0 1 0];
10
11 % do kandl = [1 0 0];
12 % do jsw = [0 1 0];
13 % do cbm = [0 0 1];
14 % do pain = [1 1 1];
15
16 % do kandl = [1];
17 % do jsw = [0];
18 % do cbm = [1];
19 % do pain = [1];
20
21 clear names x y h;
22
23 ls = {'k ' 'k:' 'k  ' 'k '};
24 lw = [1 1 1 2];
25 lc = [[0 0 0]; [0 0 0]; [0 0 0]; [0.6 0.6 0.6]];
26
27 % load data
28 load coeffs;
29
30 for n=1:length(do cbm)
31 include pain = (do pain(n)==1);
32 include kandl = (do kandl(n)==1);
33 include jsw = (do jsw(n)==1);
34 include cbm = (do cbm(n)==1);
35
36 % load JSW Data and combine
37 if (include jsm)
38 load jsw roi;
39 [id ia ib] = intersect(id, str2num(char(ROI.id)));
40 age = age(ia);
41 height = height(ia);
42 JSW = JSW(ia);
43 KL = KL(ia);
44 OP = OP(ia);
45 replace = replace(ia);
46 sex = sex(ia);
47 weight = weight(ia);
48 pain = pain(ia);
49 m{1} = m{1}(ia);
50 m{2} = m{2}(ia);
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51 m{3} = m{3}(ia);
52 m{4} = m{4}(ia);
53 m{5} = m{5}(ia);
54 m{6} = m{6}(ia);
55 mean values = mean values(ia,:);
56 meanJSM = ROI.mean JSW(ib);
57 minJSM = ROI.min JSW(ib);
58 end
59
60 % set up X and Y for mnr
61 if (include shape)
62 mnrX = [age strcmp(sex,{'male'})];% weight];
63 model = {'Constant'; 'Age'; 'Sex'};%; 'Weight'};
64 data start = 3;
65 else
66 mnrX = [age strcmp(sex,{'male'}) height];% weight];
67 model = {'Constant'; 'Age'; 'Sex'; 'Height'};%; 'Weight'};
68 data start = 3;
69 end
70 if (include pain)
71 mnrX = [mnrX strcmp(pain,{'yes'})];
72 model = [model; {'Pain'}];
73 end
74 if (include cbm)
75 mnrX = [mnrX mean values(:,1)];% mean values(:,3)];
76 model = [model; {'CTh'}];%; 'ECTD' }];
77 %mnrX = [mnrX mean values(:,1)];
78 %model = [model; {'CTh'}];
79 end
80 if (include jsm)
81 %mnrX = [mnrX meanJSM minJSM];
82 %model = [model; {'Mean JSM'; 'Min JSM'}];
83 mnrX = [mnrX minJSM];
84 model = [model; {'Min JSM'}];
85 end
86 if (include kandl)
87 mnrX = [mnrX KL];% JSW OP];
88 model = [model; {'KL'}];%; 'Min JSW'; 'OP'}];
89 end
90 if (include jsw)
91 mnrX = [mnrX JSW];
92 model = [model; {'Min JSW'}];
93 end
94 if (include shape)
95 mnrX = [mnrX m{1} m{2} m{3} m{4} m{5} m{6}];
96 model = [model; {'Shape 0';'Shape 1';'Shape 2';'Shape 3';'Shape ...
4';'Shape 5'}];
97 end
98 mnrY = [strcmp(replace,{'yes'}) strcmp(replace,{'no'})];
99 pred = {'Hip replacement'};
100 cont = 2;
101 subjects = max(size(age));
102 name = '1';
103 for m=2:length(model)
104 name = sprintf('%s + %s', name, char(model(m)));
105 end
106 name2 = '1';
107 for m=2:data start
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108 name2 = sprintf('%s + %s', name2, char(model(m)));
109 end
110
111 % normalise these values
112 mnrX = mnrX ones(subjects,1)*mean(mnrX);
113 sd = std(mnrX);
114 sd(1) = 5; % age is per 5 years, everything else is per SD
115 sd(2) = 1; % doesn't make sense dividing sex by SD
116 mnrX = mnrX./(ones(subjects,1)*sd);
117 glmY = strcmp(replace,{'yes'});
118 glmX = mnrX;
119
120 % cross validation   run the model on all bar one, then test on that one
121 disp(' ');
122 disp('                                                ');
123 gp = zeros(subjects,1);
124 if (cross validate)
125 fprintf(1,'Cross validating GLM ,,, 0');
126 for i = 1:subjects
127 fprintf(1,'\b\b\b%3i',i);
128 gX = glmX;
129 ind = [1:subjects] 6=i;
130 [gb gdev gstats] = glmfit(gX(ind,:), ...
glmY(ind,:),'binomial','link','logit');




135 [gb gdev gstats] = glmfit(glmX, glmY,'binomial','link','logit');
136 gp = glmval(gb,glmX,'logit');
137 gX = glmX;
138 end
139 [glm b gdev gstats] = glmfit(gX, glmY, 'binomial','link','logit');
140 glm p = gp;
141
142 % convert results to ROC curves
143 nr = 2001;
144 ind = mnrY==1;
145 tp glm = zeros(nr,1);
146 fp glm = zeros(nr,1);
147 for i = 1:nr;
148 tp glm(i) = sum(gp(¬ind(:,cont))>((i 1)/(nr 1)))/sum(1 mnrY(:,cont));
149 fp glm(i) = sum(gp(ind(:,cont))>((i 1)/(nr 1)))/sum(mnrY(:,cont));
150 end;
151 tp glm(1) = 1;
152 fp glm(1) = 1;
153 tp glm(nr) = 0;
154 fp glm(nr) = 0;
155
156 y(:,n) = fp glm(:,1);
157 x(:,n) = tp glm(:,1);
158 auc glm =  sum(diff(fp glm).*tp glm(1:(nr 1),:));
159 names(n) = cellstr([name ', AUC = ', num2str(auc glm(1))]);
160





165 disp(sprintf('Deviance: %.2f (%.2f including cross validation)', ...
gdev,  2*sum( glmY.*log(glm p) + (1 glmY).*log(1 glm p) ) ));
166 disp(sprintf('Degrees of Freedom: %i', size(mnrX,2)));
167 disp(' ');
168 se = gstats.se;
169 p = gstats.p;
170 disp(sprintf('\tOdds\t\t(range)\t\t\tp!=0\tCoeff'));
171 for i=1:size(gb,1); disp(sprintf('\t%.3f\t(%.3f to %.3f)\t%.5f\t %s', ...
exp(gb(i)), exp(gb(i) 2*se(i)), exp(gb(i)+2*se(i)), p(i), ...
model{i})); end
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178 for i=data start:size(gX,2);
179 gmdl = fitglm(gX(:,[1:(data start 1) i]), ...
glmY,'linear','Distribution','binomial','Link','logit');
180 gb = gmdl.Coefficients.Estimate;
181 se = gmdl.Coefficients.SE;
182 p = gmdl.Coefficients.pValue;
183 disp(sprintf('\t%.3f\t(%.3f to %.3f)\t%.5f\t %s', ...
exp(gb((data start+1))), ...
exp(gb((data start+1)) 2*se((data start+1))), ...







189 for n=1:length(do cbm)
190 h(n) = plot(y(:,n), x(:,n),char(ls(n)),'LineWidth',lw(n), 'Color', ...
lc(n,:));
191 if (n==1) hold on; end
192 end
193 legend(h, names, 'Location','SouthEast');
194 xlabel('False positive rate','FontSize',14);
195 ylabel('True positive rate','FontSize',14);
196 title('Cross validated ROC','FontSize',14);
197 set(gcf,'Color',[1 1 1]);
198 set(gca,'FontSize',14);
199 set(gcf,'Position',[600 600 650 470]);
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Appendix D
Image .wrl File Generation Matlab Script For 3D Printing
Matlab code written by Tristan Whitmarsh, adapted and commented by me to generate a
.wrl image file.
1 load thick cmaps;
2 C=thick clim1;
3 meanY percentage = 100*(slm.coef(3,:) slm.coef(2,:))./mY;
4
5 for n = 1:5580
6 t = meanY percentage(n); % Percentage changes
7 if t < C(1) % if smaller than min value then colour is
8 t = C(1); % min value (smaller than 0)
9 end
10 if t > C(2) % if bigger than max value then colour is
11 t = C(2); % max value (bigger than 0)
12 end
13
14 % values 0 70 but need values between 0 254 therefore converted
15
16 % equation to get to 0 from thickess values to a colour index
17 Ci= fix(((t C(1))/(C(2) C(1)))*size(cmap4,1))+1;
18
19 BL(n,:) = cmap4(Ci,:); % export to matlab file
20
21 if pval.C(n) > 0.05 % regions of significance (ignores
22 % values less than 0.05 and greys them out)
23 BL(n,:) = [0.7, 0.7, 0.7]; % colour choice 0.5 = grey, 0.7 = light
24 % grey, 1 = white
25 end
26
27 end
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Appendix E
Shape Mode Changes
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